Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1982

Midbrain Benzodiazepine-GABA-Serotonin Interactions: Effects on
Locomotor Activity in the Rat
Stephen Mitchell Sainati
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Medicine and Health Sciences Commons

Recommended Citation
Sainati, Stephen Mitchell, "Midbrain Benzodiazepine-GABA-Serotonin Interactions: Effects on Locomotor
Activity in the Rat" (1982). Dissertations. 2228.
https://ecommons.luc.edu/luc_diss/2228

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1982 Stephen Mitchell Sainati

MIDBRAIN

BE~ZODIAZEPINE-GABA-SEROTONIN

INTERACTIONS:

EFFECTS ON LOCm10TOR ACTIVITY IN THE RAT

by
STEPHEN HITCHELL SAINATI

A Dissertation Submitted to the Faculty of the Graduate
School of Loyola University of Chicago in Partial
Fulfillment of the Requirements for the Degree of
DOCTOR OF PHILOSOPHY

SEPTEMBER
1982

UBFU..'"\!
LOYOLA UN!VERSHY MED·~i.....'. ~'-· CSN'TER

ACKNOWLEDGENENTS

The author wishes to thank Drs. Anthony J.
Grossman, Alexander G.

Castro, Sebastian P.

Karczmar, and Louis D. van de Kar for their gui-

dance and assistance in the design and analysis of this dissertation.
An especial note of gratitude goes to Dr. Stanley A.

Lorens, Director

of this dissertation, without whose kind tutelage, counsel and support,
this work would not have been possible.
Hr.

John W.

Corliss, Department of Academic Computing Services,

must be acknowledged for his

assistance in the word processing and

printing bf the intermediate and final drafts of this discourse.
This research was supported by a grant from the United States
Department of Health and Human Services #DA-02296, and by a fellowship
from the Arthur J. Schmitt Foundation.

ii

DEDICATION

To Nother and Father, for their constant love and support,
and,
to Deanna, for making my life complete.

iii

VITA

The author, Stephen Mitchell Sainati, is the son of Bruno Sainati
and Margaret (Cook) Sainati.

He was born November 28, 1952, in Chicago,

Illinois.
His

elementary education was

obtained

at Devonshire School

Skokie, Illinois, and Ogden Avenue School in La Grange, Illinois.

in
His

secondary education was obtained at Lyons Township High School in La
Grange, Illinois, from which he was graduated in 1970.
In August,

1970, he entered Vanderbilt University in Nashville,

Tennessee, and in Hay, 1974, was graduated

cum laude with the degree of

Bachelor of Arts with a major in biology.
In April, 1978, he was admitted to and granted an assistantship in
the Department of Pharmacology at Loyola University of Chicago.

In 1980

he became a student member of the Society for Neuroscience,

and,

in

June, 1981, he was awarded a dissertation fellowship from the Arthur J.
Schmitt Foundation.

iv

TABLE OF CONTENTS
Page
. ii

ACK~m.JLEDGEHE~TS

DEDICATION

iii

. iv

VITA
Chapter
I.

INTRODUCTION

1

Benzodiazepines
Chemistry .
Pharmacological Properties
Chlordiazepoxide
Flurazepam . . . .
Midazolam . . . .
Benzodiazepines and Behavior
Appetitive Behavior . .
Avoidance Behavior
Passive Avoidance
Active Avoidance
Conflict Behavior .
Aggression . . . .
Locomotor Activity
Summary . . . . . . .
Neurotransmitter Role of GABA
Physiology . . . .
Pharmacology
Enhancement of GABA-ergic Activity
Inhibition of GABA-ergic Activity
Anatomy . . . . . . . . . .
Substantia Nigra • . .
Ventral Tegmental Area
Raphe Nuclei . . . . .
Tegmental Nuclei of Gudden
Neurotransmitter Role of Serotonin
Anatomy . . .
Physiology . . . .
Pharmacology
Serotonin Receptor Agonists
Inhibitors of 5-HT Reuptake
5-HT Releasing Agents
5-HT Precursors
. . . . .
v

2
2
6
6
9
10
10
11
13
13

14

17
18

19
20

22
22
23
24
27

28
28
30
31

32
33
33
34

35
36
36

37
37

Inhibitors of 5-HT degradation .
5-HT Antagonists . . . . . .
Inhibitors of 5-HT Synthesis
5-HT Neurotoxins . .
Serotonin and Behavior
Punished Behavior
Locomotor Activity
GABA-Benzodiazepine Interactions .
Serotonin-Benzodiazepine Interactions
Midbrain Benzodiazepine-GABA-Serotonin Interactions
Experimental Plan
II.

~1ATERIALS

AND METHODS

38
38
• 38

39
39
40
• 43

. 45
46

48
• 51

Animals
.....
Surgery
. . . . . .
Acute Intra-Raphe Injections
Chronic Intra-Raphe Cannula Placement
Electrolytic Lesions
Neurotoxic Lesions . . . .
Drugs . . . . . . . . . . . . .
Intraperitoneal Administration
Intracranial Administration
Biochemical Analysis
Histology . . . . .
Apparatus . . . . .
Statistical Analysis
III.

37

RESULTS

51
51

52
52
52
53

54
54
54
54
56
• 56
• 56
58

Experiment I:
Acute Intra-Midbrain Microinjections of Muscimol
Procedure . . . . . . . . . .
Results . . . . . . . . . .
Histolpgical Analysis
Activity Level
Conclusion . . • . . . . .
Experiment II:
Muscimol Dose-Response Relationship
Procedure . . . .
Results . . . . . . . . . .
Histological Analysis
Activity Level
Conclusion . . . . . .
Experiment III:
Interactions of Peripheral Bicuculline and
Chlordiazepoxide with Intra-Raphe Muscimol
Procedure . . . . .
. . . . . . . .
vi

58
58
59
59
64
65
. 68
68

69
69
70

75
76
77

Results
Histological Analysis
Locomotor Activity
Conclusion
Experiment IV . . . . . . . .
Experiment IVa:
Intra-Raphe Benzodiazepine Dose-Response Analysis
Procedure . . . . . . • .
Results . . . . . . . • . •
Histological Analysis .
Locomotor Activity
Conclusion . . . . . . . . .
Experiment IVb:
Intra-Raphe Bicuculline Dose-Response Analysis
Procedure • . . . . . . . .
Results . . . . . .
Histological Analysis
Locomotor Activity
Conclusion . . . . . . .
Experiment IVc:
Interactions of Intra-Raphe Benzodiazepines
with Muscimol
Procedure . . . . . . .
Results
. . . . . .
Histological Analysis
Locomotor Activity
Conclusion . . . . . . .
Experiment IVd:
Interactions of Intra-Raphe Bicuculline
with Muscimol
Procedure
Results
Histological Analysis
Locomotor Activity
Conclusion . . . . . . . . . .
Experiment V:
Muscimol Dose-Response Analysis in Animals with
Lesions in the Ventral Tegmental Nuclei of Gudden .
Procedure . . . . . . . . . . . .
Open Field Activity . . . . . . .
Two-Way Conditioned Avoidance .
Muscimol Dose-Response Analysis
Results . . . . . . . • .
Histological Analysis
Biochemical Analysis
Behavioral Analysis
Conclusion . . . . .
vii

78
78
78
81
. 84

85
85

86
86
86
91
92
92
92
. 92
92
93

94
•• 94
94
94
95
98

101
101
101
101
101
102
105
106
106
107
108
108
108
111
114
115

Experiment VI:
Huscimol Dose-Response Analysis in Animals with
Lesions of the Ascending 5-HT Projections .
Procedure . . . . . . . .
Results . . . . . . . . •
Histological Analysis .
Biochemical Analysis
Behavioral Analysis
Conclusion
IV.

DISCUSSION

118
118
119
119

122
125
125
128

General Discussion
Proposals for Future Research .
REFERENCES

128
138
140

Appendix
A.

APPROVAL SHEET

163

viii

LIST OF TABLES
Page

Table

1.

Interaction of intra-raphe benzodiazepines with muscimol.

. 96

2.

Intra-raphe bicuculline interactions with muscimol. . . .

103

3.

Effects of VTG lesions on regional 5-HT and 5-HIAA levels.

112

4.

Effect of 5,7-DHT on regional 5-HT and 5-HIAA levels. .

123

ix

LIST OF FIGURES
Page

Figure
1.

Structures of benzodiazepine nucleus and subclasses.

4

2.

Structures of benzodiazepines used in present study.

7

3.

Photomicrograph of median raphe U1R) needle tip.

60

4.

Photomicrograph of dorsal raphe (DR) needle tip.

62

s.

Activity scores after acute muscimol injection.

66

6.

Dose-activity effects of intra-raphe muscimol . .

71

7.

Temporal effects of intra-raphe muscimol injections.

73

8.

Chlordiazepoxide potentiates the muscimol effect.

79

9.

Bicuculline blocks the muscimol effect.

82

10.

Intra·raphe benzodiazepine dose-response relationship.

87

11.

Temporal effects of intra-raphe benzodiazepines . . . .

89

12.

Interaction of intra-raphe benzodiazepines with muscimol

99

13.

VTG lesion and HR cannula placement sites.

109

14.

Effects of VTG lesions on muscimol-induced hyperactivity

116

15.

Photomicrograph of a midbrain 5,7-DHT injection site.

120

16.

Forebrain S·HT depletion blocks the effect of muscimol.

126

X

ABSTRACT
Acute microinjections of the GABA-agonist, muscimol, into the dorsal or median raphe nucleus of ether-anesthetized rats induced hyperkinesis as measured in photocell activity chambers.

The median raphe

nucleus is more sensitive to the effect of muscimol than the dorsal
raphe nucleus.

A dose-response analysis performed by injecting muscimol

through cannulae chronically implanted in the dorsal or the median raphe
nucleus of rats confirmed the greater sensitivity of the median raphe
site.

Intraperitoneal administration of the benzodiazepine, chlordiaze-

poxide, in a subataxic dose did not affect activity level, but enhanced
the

locomotor responses

median raphe nucleus.
sub-convulsant
blocked the

dose

r~sponse

to

low doses of muscimol

Conversely,
of

the

injected into the

intraperitoneal administration of a

GABA-antagonist,

bicuculline,

completely

to muscimol.

Subsequently, dose-response analyses for the water soluble benzodiazepines, chlordiazepoxide, flurazepam,

and midazolam were performed

by injecting the drugs through cannulae chronically implanted in the
median raphe nucleus of rats.
hyperactivity which
post-injection.
olam.

Both midazolam and flurazepam produced

was most prominent

within the

first

30 minutes

Flurazepam, moreover, proved twice as potent as midaz-

In contrast, chlordiazepoxide was without effect at any of the

doses tested.

xi

~ext,

animals received either saline or a sub-effective dose of

flurazepam or midazolam into the median raphe nucleus 5 minutes prior to
either a sub-effective dose of muscimol or saline.

Only the combina-

tions of a benzodiazepine plus muscimol produced hyperactivity.

These

combinations, moreover, produced effects as robust as those of a fourfold higher dose of muscimol alone.
In another experiment, animals received either saline or bicuculline methiodide

injections

into the

median raphe nucleus

5 minutes

before they received a hyperactivity-inducing dose of muscimol.

Bicu-

culline completely blocked the hyperactivity effects of muscimol.

Ove-

rall, these data suggest that the hyperkinetic effects of intra-raphe
muscimol injections are due to activation of GABA receptors within the
midbrain raphe, rather than at distant sites.
In a subsequent experiment, bilateral electrolytic destruction of
the ventral tegmental nuclei of Gudden, which lie just dorsolateral
, to
the median raphe nucleus,

produced an increase in baseline activity

level, but failed to alter the median raphe muscimol dose-response relationship.
Finally,

forebrain

serotonin

was

5,7-dihydroxytryptamine intracerebrally.

depleted

by

administering·

These lesions markedly attenu-

ated the hyperactivity response produced by muscimol injections into the
median raphe nucleus.

These data suggest that midbrain GABA neurons

modulate activity level through a direct action on serotonergic neurons.
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CHAPTER I

INTRODUCTION
The benzodiazepines were introduced into clinical medicine in the
early 1960's.

They quickly became the most commonly prescribed class of

pharmaceuticals.

Today,

some 20 years after their introduction,

the

benzodiazepines are used widely as sedative-hypnotic, anti-convulsant,
anti-anxiety,

muscle-relaxant

and pre-anesthetic drugs.

Since

1976,

more than 100 million prescriptions for the benzodiazepines have been
written annually in the United States alone (Harvey, 1980).
There is a consensus that the benzodiazepines exert their behavioral

and

physiological

effects

by

facilitating

the

action of the inhibitory amino acid neurotransmitter,
tyric acid

(GABA;

Haefely

et al.,

1975;

cells

constitute

local

within a given brain structure.

circuit

gamma-aminobu-

Costa and Guidotti,

Krogsgaard-Larsen and Arnt, 1980; Olsen, 1982).
releasing

post-synaptic

1979;

For the most part, GABA

neurons,

or

interneurons,

These GABA-ergic cells, which are dis-

tributed throughout the neuraxis, modify the operation of other neurons
which often utilize a neurotransmitter other than GABA.

GABA interneu-

rons thus modulate the inputs and outputs of a given brain region and,
thereby, its function.

As facilitators of GABA neurotransmission, it is

r.ot surprising that the benzodiazepines can produce profound behavioral
effects.

1

2

It is the objective of the present work to elucidate the role of
midbrain GABA and benzodiazepine receptors in the modulation of locomotor activity, and to determine whether this regulatory function is mediIn order to provide a background for

ated by a serotonergic system.

this research effort, the following topics will be reviewed:

1) the

pharmacology of the benzodiazepines; 2) the behavioral effects of the
benzodiazepines; 3) GABA and serotonin as neurotransmitters; 4) GABAbenzodiazepine interactions;

5) serotonin -benzodiazepine

interactions;

and, 6) the modulation of midbrain raphe neurons by GABA and benzodiazepine receptors.
Benzodiazepines
Chemistry
The nucleus of the benzodiazepine molecule is depicted in Figure 1
At the 7-position, electronegative groups enhance,
groups reduce potency.
activity.

Substituents

and electropositive

elsewhere in this ring decrease

A wide variety of moieties may occupy positions 1 to 3.

A

low electron density at the 4-nitrogen, provided by a double bond between positions 4 and 5, or by an electron-withdrawing group at position
4, is common to all clinically useful benzodiazepines.

An electronega-

tive 2'-substituent (ortho) on the 5-phenyl moiety will enhance potency
(Harvey, 1980).
Substitutions have led to four basic classes of the benzodiazepines (Figure 1):

the 1) 2-keto- ; 2) triazolo- ; 3) 3-hydroxy- ; and,

4) the 7-nitro- benzodiazepines.

These different classes of benzodiaze-

3

pines all possess anti-convulsant, anti-anxiety, sedative-hypnotic, and
muscle-relaxant properties. It is the differences in their pharmacokinetics which largely determine their clinical application (Johnson and
Rising, 1979; Breimer

et al., 1980).

A major problem associated with

the 2-keto- benzodiazepines, which include the often prescribed sedative-hypnotic, flurazepam, and the multipurpose drug, diazepam,

is the

production of long-acting (half-life 50 - 100 hours) active metabolites
(Benet and Scheiner, 1980; Breimer
pines, such as prazepam,
appear to serve

et al., 1980).

chlorazepate,

as pro-drugs

for

Certain benzodiaze-

and possibly chlordiazepoxide,

the

2-keto- metabolites (Curry and Whelpton,

formation
~979).

in

vivo of active

These compounds, thus,

find clinical utility in the treatment of anxiety-neuroses where longterm steady-state plasma levels of drug (or active metabolite) are desirable (Baldessarini, 1980).

A 7-nitro- group (as contained, for exam-

ple, in clonazepam; Figure 1) increases anti-convulsant activity CRall
and

Schleifer,

1980).

Furthermore,

the

7-nitro-benzodiazepines

are

reduced to inactive 7 -amino- derivatives,

the parent compounds having

half-lives

and

ranging

between

15

37

hours.

The

3-hydroxy-benzodiazepines have short half-lives (8. 5 - 15 hours), plus
the advantage of being conjugated at the 3-position to form inactive
glucuronide derivatives which are excreted directly (Benet and Scheiner,
1980;

Breimer

et al.,

1980).

F.inally,

the triazolo-benzodiazepines

have very short half-lives (2.5 - 11 hours).

They are oxidized to form

compounds which do not cross the blood-brain barrier and are rapidly

4

FIGURE 1:

Structures of benzodiazepine nucleus and subclasses.
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excreted following oxidation (Johnson and Rising, 1979; Pieri
1981).

et a1.,

For more complete reviews of benzodiazepine structure-activity

relationships,
and Shader

the reader is referred to Sternbach ( 1973), Greenblatt

(1974),

Johnson

and Rising

(1979),

and

Breimer

et

al.

(1980).
Pharmacological Properties
In the present study, three different benzodiazepines have been
employed.

These drugs were selected primarily because they are all

water soluble, but show distinct pharmacokinetic properties.

We thus

will concentrate on these agents, the structures of which are shown in
Figure 2:

1) chlordiazepoxide; 2) flurazepam; and, 3) midazolam.

Chlordiazepoxide·
Chlordiazepoxide was the first benzodiazepine marketed as a "minor
tranquilzer" or anxiolytic drug.

It was synthesized in 1955 by Stern-

bach, and its sedative-hypnotic and anti-anxiety effects were discovered
not long after

(Greenblatt and Shader,

1974).

Unstable in solution,

preparations for parenteral administration must be
used

immediately.

When

injected

intravenously

into mice,

immediate uptake of radio labeled chlordiazepoxide
kidney,

liver,

and skeletal muscle.

freshly mixed and
there

into brain,

is

heart,

Brain radioactivity at first is

more concentrated in neocortex and thalamus, but within 10 minutes after
injection the label is distributed evenly throughout the brain (Placidi

7

FIGURE 2:

Structures of benzodiazepines used in present study.
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and

1968).

Cassaro,

Within

several

hours,

the

label

becomes

concentrated in excretory organs.
Chlordiazepoxide is extensively (87-88%) bound to plasma proteins,
especially albtimin
chlordiazepoxide,
however,

is

(Greenblatt and Shader,
itself,

is

approximately

somewhat misleading.

centrally-active metabolites,

such

1974).

10 hours.

The parent
as

The half-life of

drug

is

This

figure,

converted to

desmethyl-chlordiazepoxide

and

demoxepam, the latter compound having a reported half-life of up to 95
hours (Greenblatt and Shader, 1974).

In fact, the anxiolytic effect of

chlordiazepoxide in humans is better correlated with the steady-state
concentrations

of

these

metabolites

than with

the

plasma

level

of

chlordiazepoxide itself (Lin.and Friedel, 1979).
Flurazepam
Flurazepam, a 2-keto-benzodiazepine, is very rapidly metabolized,
having a plasma half-life of less than 2 hours (Greenblatt and Shader,
1974).

As is the case with chlordiazepoxide, flurazepam is converted to

active metabolites.

Although flurazepam,

itself, is centrally active,

the desamino- and desalkyl- metabolites are an order of magnitude more
potent, and reach higher plasma levels than the parent compound (Hasegawa and Hatsubara, 1975; Harvey, 1980).

The elimination half-life of

the desamino- compound approximates 20 hours, while that of the desalkyl- metabolite approaches 100 hours (Breimer, 1977).
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Midazolam
Midazolam is a triazolo-benzodiazepine, which is characterized by
an imidazole ring fused to positions 1 and 2 of the diazepine ring.

The

compound first was synthesized by Walser and collaborators (1978).

The

imidazole ring confers a high stability in aqueous solution and a short
duration of action (Pieri

et al., 1981). After intravenous administra-

tion the plasma half-life of midazolam ranges from 1.3 - 2.5 hours (Lauven

et al., 1981; Amrein et al., 1981).

is demethylation to form

alpha-hydroxymidazolam, which subsequently is

conjugated with glucuronic acid.

In addition, oxidation can occur at

position 4 yielding 4-hydroxymidazolam and
(Walser

The major route of metabolism

alpha,4-dihydroxy- midazolam

et al., 1978.) The non-conjugated metabolites are markedly less

potent than the parent compound

in vivo, primarily due to their poor

penetration of the blood-brain barrier (Pieri

et al., 1981). Midazolam

has a rapid onset of action (Heizman and Ziegler, 1981; Crevoisier

et

al., 1981.) This property, combined with its short duration of action,
solubility in aqueous vehicle,

and lack of active metabolites,

make

midazolam ideal for animal studies in which repeated daily injections
are needed.
Benzodiazepines and Behavior
In view of the clinical effects of the benzodiazepines, it is not
surprising that these compounds produce striking behavioral changes when
administered to laboratory animals.

In order to facilitate this review,

studies concerning the behavioral effects of the benzodiazepines will be

11

discussed under one of the following rubrics:

1) appetitive behavior,

2) avoidance behavior, 3) conflict behavior, 4) aggressive behavior, and
5) locomotor activity.
Appetitive Behavior
The effects of the benzodiazepines on appetitive behavior are critically dependent upon the nature of the reward and the specific experimental paradigm employed.
reinforcers

In general, two different primary positive

(reward) have been used:

a) consummatory reward, and b)

electrical brain stimulation reward (BSR; Olds and Milner, 1954).

To

date, no consistent effects of benzodiazepines on responding for consummatory reward (for example, food or water) have been demonstrated (for
excellent reviews, see Gray, 1977; and, Morley, 1980).

With regard to

responding for BSR, the benzodiazepines have been reported both to facilitate and to depress operant responding.

In ieneral, low doses of the

more potent anxiolytic benzodiazepines, such as diazepam and chlordiazepoxide, enhance responding for BSR (Olds, 1966; Panksepp

et al., 1970;

Wauquier, 1976), while sedative-hypnotic benzodiazepines, such as nitrazepam, produce a depression of response (Wauquier, -1976).

In our own

laboratory, we have noted a response enhancement following low doses
(1.0 - 2.0 mg/kg, intraperitoneally) of midazolam (Sainati and Lorens,
unpublished).

The

duration of the

chlordiazepoxide- induced response

enhancement greatly exceeds the presence of detectable amounts of chlordiazepoxide in serum (Wauquier, 1974; Lorens and Sainati, 1978).

This

probably is due to the conversion of chlordiazepoxide to active metabol-

12
ites having very long durations of action (see above).

One possible

explanation for the benzodiazepine-induced response enhancement is that
these and other drugs with abuse

liability may release an endorphin

whose effect on opiate receptors mediates the drug-induced alterations
in BSR (Lorens, 1976; Stein, 1978; Lorens and Sainati, 1978).
A drug with abuse liability in humans might be expected to be
self-administered by laboratory animals.

Although more difficult to

establi&h than with opioids and stimulants, both oral and intravenous
self-administration of benzodiazepines has been obtained

(Harris

et

al., 1968; Findley et al., 1972; Davis et al., 1976; Walton and Deutsch,
1979).

These findings suggest that in addition to their effects on ope-

rant responding for BSR or

consummatory reward,

the benzodiazepines

themselves have a positively reinforcing property.
In contrast to the primary reinforcement hypothesis both Stein

et

al. (1977) and Wauquier (1976; 1979) have postulated that the facilitatory effects of the benzodiazepines on BSR may be due to a release from
a punishing component of the stimulation.

Benzodiazepine-induced beha-

vioral facilitation is seen most clearly in situations where rewarded
behavior is suppressed by punishment (Wauquier,

1979).

Although the

anatomical substrates which mediate BSR have yet to be deliniated, the
medial forebrain bundle appears to play an important role (Olds
1960; Lorens,

et al.,

1976). According to Stein and coworkers (1977), BSR is

mediated by catecholamine systems in the brain.

Indeed, nor adrenergic

fibers from the locus coeruleus [(A-6, in the classification of Dahlst-

13
rom and Fuxe, 1964)], and dopaminergic fibers from the substantia nigra
(A-9) and ventral tegmental area of Tsai (A-10), do ascend in the medial
forebrain bundle (Lindvall and Bjorklund, 1978; Moore and Bloom, 1978;
Bloom and Moore, 1979).

Although some evidence suggests that dopamine

neurons are important in the mediation of BSR, it appears that noradrenergic systems do not play a critical role (Fibiger, 1978).

Ascending

5-HT fibers, originating in the mesencephalic dorsal and median raphe
nuclei, also have been found in the medial forebrain bundle (Azmitia and
Segal, 1978).

The ascending 5-HT systems have been implicated as form-

ing a component of a "punishment system" (Wise

et al., 1972; Stein et

al., 1973). The inhibition of this system theoretically would produce a
release from punishment and a resultant enhancement in responding.
Avoidance Behavior

Passive Avoidance
Passive avoidance is a term used to describe the learned suppression of approach behavior toward a particular place or stimulus.
example,

following

receipt of electrical

foot shock for

For

entering a

designated area of a testing apparatus, the animal learns to refrain
from returning

to that

section of

involves spatial discrimination.

the apparatus.

Such a

paradigm

The benzodiazepines tend to impair

passive avoidance acquisition and retention (Gray, 1977).

Such effects

have been seen with relatively high doses of chlordiazepoxide (7.5 - 60
mg/kg) and diazepam (6-24 mg/kg) in both rats and mice (Fuller, 1970;

14

Morrison and Stephenson, 1970; Kumar,
mice

a

similar

disruption

1971; Oishi

of passive

avoidance

et al.,

1972).

retention has

In

been

reported following the ·administration of diazepam (10 mg/kg), lorazepam
(20 mg/kg) and flurazepam (1.0 mg/kg)

(Jensen et al., 1979).

Active Avoidance
Active avoidance is a general term used to describe experimental
paradigms in which the animal must emit an operant response in order to
avoid an aversive stimulus,

such as an electric shock to the feet.

Active avoidance paradigms may involve spatial (for example, the animal
must move from one part of a test apparatus to another in order to avoid
an electric shock) or non-spatial [for example, lever-pressing as in the
paradigm of Sidman (1953)] operants (Gray, 1977).
One-Way Active Avoidance
In one-way active avoidance procedures, the subject is required
always to move in one same direction to avoid an aversive stimulus.
Thus, the spatial cues in the animal's surroundings become conditioned
stimuli (CS).

In most one-way avoidance test situations, benzodiaze-

pines have little effect on acquisition of the task, but do tend to
reduce the response latency (Gray, 1977).
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Two-Way Active Avoidance
In two-way (shuttlebox) active avoidance, the animal is placed in
one side of a two-compartment chamber. A warning signal (CS)
sented.

is pre-

At a given time (for example, 5 seconds) after the onset of the

cs, the animal receives an unconditioned stimulus, electrical footshock,
until it escapes to the other side of the apparatus.

On the next trial,

the process is repeated, only now the animal must return to the side
where it originally was shocked.

This represents a conflict between

active and passive avoidance (Gray, 1977) because the subject naturally
will be

reluctant to return

to the side

from which it

just fled.

Accordingly, treatments which disrupt an animal's ability to utilize
spatial cues may facilitate two-way avoidance acquisition.
The facilitatory effect of chlordiazepoxide on shuttlebox performance in rats and mice is well known (Fuller, 1970; Iwahara, 1971; Gray,
1977; Sansone and Vetulani, 1980).

In general,

this facilitation is

seen only after high doses, that is, those sufficient to suppress spontaneous locomotor activity (for example, 8.0 - 20 mg/kg).

In our labo-

ratory, chlordiazepoxide in doses of 4.0 - 8.0 mg/kg tends to facilitate
two-way avoidance acquisition during 50 massed trials, but this effect
rarely
lished).

reaches statistical

significance

(Sainati

and Lorens,

unpub-

This finding is in agreement with observations made by Takao-

ri's group (1969), who reported that there is a tremendous variability
in the performance of control animals even among littermates from the
same strain.

Midazolam (2. 0 - 4. 0 mg/kg), while failing to improve
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acquisition of the two-way avoidance task, does increase the number of
spontaneous inter-trial barrier crossings

(Sainati and Lorens, unpub-

lished)·
Sidman Avoidance
Sidman avoidance paradigms represent a non-spatial avoidance task
(Gray,
with

1977).
a

Briefly, the subject is placed in a chamber outfitted

manipulandum

(Skinner

box)

and

an

electrifiable

grid

floor

through which shocks are programmed to occur at regular intervals unless
the subject performs the appropriate response (for example, lever-pressing).

With a proper response, the animal can postpone the next shock

for a certain period of time (Sidman, 1953; Heise and Boff, 1962).

In

general, low doses of benzodiazepines facilitate avoidance responding,
especially . in
state.

animals whose performance

is poor

in the non-drugged

High doses, in contrast, suppress avoidance behavior especially

in animals with good performance in the non-drugged state (Gray, 1977).
Similar results have been obtained for chlordiazepoxide, diazepam (Bignami

et al.' 1971), nitrazepam (Takaori et al., 1969), tempazepam (Lon-

goni

et al., 1973), flurazepam (Randall and Kappell, 1973), and

olam (Pieri et

al.,

1981).

Gray

(1977)

and Bignami

et al.

midaz(1971)

suggest that the benzodiazepines improve performance in the Sidman avoidance paradigm by reducing the suppressant effects of the apparatus cues
associated with the shock.

This hypothesis renders the Sidman avoidance

paradigm a type of "conflict" test, as will be discussed below.
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Conflict Behavior
Of the psychopharmacological techniques available for studying the
effects of anti-anxiety agents (for review see Bignami, 1976), among the
most routinely employed are those involving operant conditioning techniques in a Skinner box (Gray,

1977; Sepinwall and Cook,

1978).

Such

methods have achieved popularity because experimental animals can be
used as their own controls, owing to the stability of baseline data in
trained animals (Cook and Sepinwal1, 1975a).
Geller and Seifter

(1960;

The conflict paradigm of

1962) has been used widely

effects of anxiolytics in laboratory animals.

to study the

Briefly, this procedure

involves a schedule in which periods of intermittent food reinforcement
are alternated with periods during which continuous food reinforcement
is

available,

but

in

combination

with

footshock

punishment.

creates in the animal an approach- avoidance "conflict."
flict" procedure is

This

Another "con-

the lick-suppression test of Vogel and coworkers

(1971), which consists of suppression of drinking by shocks administered
through the drinking tube.

The benzodiazepines, along with other clini-

cally effective anxiolytics (for example, meprobamate), enhance responding for food reward during the punished (conflict) segment, but not during the

non-punished segment.

flurazepam, nitrazepam,

Diazepam,

chlordiazepoxide,

oxazepam,

flunitrazepam and midazolam, as well as other

benzodiazepines, share this property (Geller

et al., 1962; Margules and

Stein, 1968; Stein et al., 1973; Gray, 1977; Sepinwall and Cook, 1978;
Lippa

et al., 1979; Malick and Enna, 1979; Pieri et al., 1981).

These
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drugs possess little analgesic potency (Bignami, 1976), and classical
analgesics,

such as

morphine,

possess

little anti-conflict

activity

(Sepinwall and Cook, 1978).
The notion that the anti-conflict effect of the benzodiazepines
represents an animal model for predicting the antianxiety property of a
compound in humans is strongly supported by the nearly perfect correlation between the minimum effective doses of various anxiolytics in rat
anti-conflict tests and the average daily clinically effective dose for
the treatment of human anxiety neuroses
Lippa et al.,

(Cook and Sepinwall,

19 7Sb;

1978). The correlation between receptor binding potency

and rat anti-conflict potency for various benzodiazepines also is excellent (Hohler and Okada, 1977a; Sepinwall and Cook, 1980).

Moreover, the

anti-conflict property of the benzodiazepines has· been demonstrated in
every species tested to date (Sepinwall and Cook, 1978).
Aggression
In various animal models of aggression, the benzodiazepines, as
well as non-benzodiazepine anxiolytics, selectively decrease aggressive
behavior in a number of species (Gray, 1977; Harvey, 1980).

The experi-

mental paradigms employed have included experimenter provocation, electric shock, and isolation-induced aggression (Delgado,
and Maxwell, 1970; Valzelli, 1973).

1973; Christmas

It has been reported, however, that

rat muricidal behavior is enhanced following benzodiazepine administration (Harvey, 1980).

One possible explanation for this apparent paradox

is the hypothesis of Hoffmeister and Wuttke (1969) that the benzodiaze-
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pines diminish defensive aggression, but enhance offensive aggression.
Fighting induced by footshock or isolation would represent defensive
aggression, whereas muricide would represent offensive aggression (predation).
Locomotor Activity
The effects of the benzodiazepines and other minor tranquilizers
on spontaneous

locomotor activity are dose-dependent

(Greenblatt and

Shader, 1974).

At low doses, activity remains at baseline level, while

at high doses, toxicity ensues and activity is reduced (Marriott and
Spencer, 1965; Christmas and -Maxwell, 1970; Hughes, 1972).
doses tend to increase activity level.

Intermediate

The effects of a given dose,

however, are highly variable even within a given species.

In rats,

activity-enhancing doses of chlordiazepoxide range between 5.0 and 30
mg/kg; the effective doses for diazepam and nitrazepam are between 0.5
and 5.0

mg/kg

(Greenblatt

and Shader,

1974).

Flurazepam tends

to

enhance locomotor activity in doses from 1.0 to 10 mg/kg (File and Hyde,
1979; Crawley, 1981).

Midazolam has been reported to enhance activity

in lighted Animex chambers, but only after the dose of 5.0 mg/kg (Pieri
et al., 1981).
When evaluating the effect of any drug on locomotor activity, it
is essential to pay particular attention to the experimental conditions
employed.

Rats and mice will approach a novel environment cautiously

and tend to choose a familiar environment when given a choice (Greenblatt and Shader, 1974; File and Hyde, 1979).

It is important, thus, to
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know whether the animal is familiar or unfamiliar with the test situation (Marriott and Spencer, 1965; Christmas and Maxwell, 1970; Hughes,
1972).

There are many reports of increases in exploratory behavior fol-

lowing benzodiazepine administration (Greenblatt and Shader, 1974), or
of increased preference for a novel setting over a familiar one (Marriott and Spencer, 1965; Hughes, 1972; File and Hyde, 1979; File, 1980;
Crawley, 1981).
Inasmuch as rats are nocturnal animals, the lighting conditions of
the experimental surrounding also have an important influence on the
locomotor response to a drug.
taxic doses,

Although the benzodiazepines, in suba-

tend to increase locomotor activity in a lighted arena

(Marriott and Spencer, 1965; Christmas and Maxwell, 1970; Hughes, 1972),
they have little effect on activity level when measured in dark photocell cages (Krsiak

et al., 1970; Pieri et al., 1981). This difference

could be explained by the hypothesis that novel, lighted arenas are more
fear or anxiety-producing, so that the anxiolytic benzodiazepines can
release a fear-induced suppression of locomotor activity.
Summary
The benzodiazepines are an important class of drugs with several
clinical applications.
diazepines

also are

Recently it has become clear that the benzo"abused",

or

"recreationally" used,

substances,

often in combination with ethanol and/or the barbiturates.

The benzo-

diazepines appear to have positively reinforcing effects in that they
are self-administered by animals and man (Woods, 197?), and can enhance
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responding

for

brain·stimulation

dis inhibit punished behaviors.
experimental paradigms

reward.

This

which employ

The

benzodiazepines

also

is most clearly demonstrated in
"conflict," such

Seitter procedure and the lick-suppression test.

as

the Geller-

The effects of the

benzodiazepines on other behaviors controlled by painful stimuli appear
to be task-dependent.

Thus, for example, the benzodiazepines can faci·

litate two·way active avoidance acquisition, but fail to influence the
acquisition of a one-way conditioned avoidance response.
the benzodiazepines can affect
experimental parameters employed.
exploratory

and locomotor

locomotor

activity,

In addition,

depending on the

The benzodiazepines appear to modify

activity predominantly

in test

situations

which contain a high degree of novelty or fear-inducing stimuli.
behavioral effects

of the benzodiazepines

These

long have been viewed as

reflective of their sedative and anxiolytic properties.
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Neurotransmitter Role of GABA

-----

One of the major inhibitory neurotransmitters in the central nervous system (CNS) is

gamma-aminobutyric acid (GABA) (Baxter, 1970; De

Feudis, 1975; Johnston, 1978).

Several indices have been considered and

explored in attempts to demonstrate GABA-ergic neurons (Cooper

~

al.,

1978):
The presence and concentration of GABA, itself.
The presence and activity of the enzyme, glutamic acid decarboxylase (GAD), which catalyzes the conversion of glutamate to
GABA.
The presence and activity of the metabolizing enzyme, GABAtransaminase (GABA-T).
The high-affinity uptake of GABA.
GABA receptor localization.
Biochemical (Gabellec

et al.,

1980), immunohistochemical (Barber and

Saito, 1975; Saito, 1976) and autoradiographic (Privat, 1976) studies of
these indices have shown that GABA serves as a neurotransmitter throughout the neuraxis (in the spinal cord, the cerebellum, the neostriatum,
the neocortex, and many other brain regions).
Physiology
GABA functions as an inhibitory synaptic transmitter throughout
the mammalian CNS.

Although the net effect of GABA always is inhibi-

tory, this effect can be produced either by pre-synaptic depolarization,
such as in the spinal cord substantia gelatinosa (Nishi

et al., 1974;
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Nicoll and Alger, 1979; HcGeer and HcGeer, 1981), or by post-synaptic
hyperpolarization, such as commonly seen at higher levels in the CNS
(MacLeod

et al., 1980; Harciani et al.,

McGeer and HcGeer, 1981).

1980; Hatthews et al., 1981;

Both the pre-synaptic depolarization and the

post-synaptic hyperpolarization responses produced by GABA are brought
about by an increase in the permeability of membranes to chloride ions.
The response of post-synaptic neurons to GABA is determined by the
interaction between two distinct membrane units, the GABA t:eceptor and
the chloride ionophore.

When GABA binds to its receptor, the chloride

ion channel opens and allows a redistribution of chloride across the
neuronal

membranes

along

the

electrochemical

concentration gradient

(Roberts, 1974; Costa and Guidotti, 1979; Olsen, 1982).

An increase in

permeability to chloride usually produces hyperpolarization due to an
influx of chloride ions.

The presynaptic depolarization, however, pro-

bably is due to an efflux of chloride from the nerve terminals, since
these

terminals

contain

relatively

high

concentrations

of

chloride

intracellularly (Roberts and Hammerschlag, 1976).
Pharmacology
GABA is formed by the one-step decarboxylation of the
acid, glutamate.

alpha-amino

This reaction is catalyzed by 1-glutamic acid decar-

boxylase (GAD), an enzyme with an absolut~ requirement for the cofactor
PYridoxal phosphate (vitamin B-6).
up by specific,

Synaptically released GABA is taken

sodium-dependent high-affinity reuptake systems

both presynaptic nerve terminals and surrounding glial cells.

into

The major

24
route of metabolism is by transamination with
the enzyme GABA-transaminase (GABA-T).
cinic semialdehyde, is

alpha-ketoglutarate via

The resultant metabolite, sue-

rapidly oxidized to succinic acid by succinic

semialdehyde dehydrogenase (SSA-DH). · For a review of GABA.metabolism,
see Roberts and Hammerschlag (1976).
Various pharmacological manipulations may be employed to alter
GABA neurotransrnission.
Enhancement of GABA-ergic
activity
Drugs can produce GABA-mimetic effects either by acting as ligands
directly at the GABA receptor, or indirectly by increasing the availability

or affinity of GABA for the receptor

pos~-synaptically.

Directly acting receptor agonists
A number of conformationally restricted GABA analogues have been
reported to be GABA receptor agonists (Johnston, 1978; Enna and Maggi,
1979; Andrews and Johnston,

1979).

Among the purported GABA agonists

are muscimol (Johnston, 1978; Baraldi

et al., 1979; Beaumont et al.,

1979; Worms et al., 1979), 4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridine3-ol (THIP; Maurer, 1979; Arnt and Krogsgaard-Larsen, 1979), isoguvacine
(Andrews and Johnston, 1979), kojic amine (Yarbrough
SL76-002 (Bartholini et al.,

1979).

et al., 1979) and

With the exception of SL76-002,

none of these drugs crosses the blood-brain barrier in appreciable concentration (Johnston, 1978; Baraldi
nature of SL76-002,

et al., 1979). The direct-agonist

moreover, recently has been questioned (Enna and
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Maggi, 1979).

For intracranial injections, muscimol has become the most

widely used GABA receptor agonist due to its high affinity for the GABA
receptor

in vitro.

For this reason, muscimol has been used extensively

in the present series of experiments.
Indirectly acting agents
Indirectly acting GABA-mimetics include GABA reuptake inhibitors,
releasing agents,

inhibitors of degradation,

and allosteric receptor

ligands, such as the benzodiazepines.
Inhibitors of GABA uptake:
minals (Varon

GABA is taken up both into nerve ter-

et al., · 1965) and glial elements (Henn and Hamberger,

1971; Sellstrom and Sjoberg, 1975; Varon and Somjen, 1979) by specific
high-affinity membrane transport systems.
can be distinguished pharmacologically.

These two specific systems

There are drugs which are rela-

tively specific ,for nerve-terminal reuptake and others which are relatively specific for glial uptake of GABA.

Among the relatively selec-

tive substrates for neuronal reuptake are 1-2,4-diaminobutyric acid,
nipecotic acid,

guvacine and

cis-3-aminocyclohexane

(Iversen, 1978; Johnston, 1978; Wood
inhibited by such drugs
1978; Schousboe

as

carboxylic acid

et al., 1979). Glial reuptake is

beta-alanine and beta-proline

(Johnston,

et al., 1979). These specificities, however, are only

relative (De Feudis

et al., 1979).

The high-affinity uptake of labeled GABA can be used to identify
GABA-ergic structures autoradiographically (Hokfelt and Ljungdahl, 1971;
Iversen, 1978).

These results must be interpreted cautiously, however,
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because the correlation between the rate of GABA uptake, GAD activity
and GABA levels tends to vary (Storm-Mathisen, 1975; Fonnum and StormMathisen, 1978).
GABA releasing agents:
GABA releasing drug.
baclofen is

At present, baclofen is the only known

A sterically-hindered structural GABA analogue,

thought to exert

its muscle-relaxant activity through a

release of intracellular GABA stores (Andrews and Johnston, 1979).
Inhibitors

of

GABA

degradation:

Selective

inhibition

of

the

enzymes GABA-T or SSA-DH usually leads to increased levels of CNS GABA.
This phenomenon is correlated with an anticonvulsant effect (Johnston,
1978).

Amino-oxyacetic acid is a potent inhibitor of GABA-T, and is

used very commonly to increase brain GABA levels.
nyl-trapping agent,
other

amino-oxyacetic acid also

transaminase enzymes

(Johnston,

1978;

A non-specific carboinhibits GAD and many

Metcalf,

1979;

Loscher,

1980).
Ethanolamine-a-sulfate is an excellent specific irreversible inhibitor of GABA-T.
barrier.

This drug, however, does not penetrate the blood-brain

Gamma-acetylenic GABA, gamma-vinyl-GABA and gabaculine act

quite similarly to ethanolamine-a-sulfate, and, moreover, do cross the
blood-brain barrier (Johnston, 1978; Loscher, 1980; Palfreyman

et al.,

1981).
Sodium

di-g-propylacetate

(sodium

valproate)

is

a

clinically

effective anti-convulsant which acts more by inhibiting SSA-DH than by
any action on GABA-T (Johnston, 1978; Palfreyman

et al., 1981). All of
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the aforementioned agents are effective in elevating central nervous
system GABA levels.
Allosteric

ligands:

The

evidence that

benzodiazepines act

to

facilitate GABA-ergic transmission by a modulatory effect on an allosteric post-synaptic site will be reviewed below.
Inhibition of GABA-ergic
activity
Receptor antagonists
Bicuculline:

This convulsant drug which has been employed in the

present work, is a specific competitive GABA-receptor antagonist (Mohler
and Okada, 1977h; Johnston, 1978).
bleat physiological pH (Olsen

Being insoluble in water and unsta-

et al., 1975), (+)-bicuculline must be

dissolved in an acidic vehicle for parenteral administration.

Salt der-

ivatives which are water soluble, such as bicuculline hydrochloride and
bicuculline methiodide, are more suitable for direct intracranial injection.

When administered parenterally, however, these compounds, in con-

trast to (+)-bicuculline, do not cross the blood-brain barrier.
Picrotoxin:

This convulsant does not influence the binding of

GABA to synaptic membranes. Instead, it interferes with the opening of
the GABA-specific chloride ionophore, which is necessary for the postsynaptic neuronal response (Johnston, 1978; Olsen

et al., 1979). Thus,

it seems that picrotoxin does not affect the interaction of GABA with
GABA receptors, but rather the membrane molecules responsible for controlling chloride ion flux (Johnston, 1978).
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Inhibitors of GABA synthesis
3-Mercaptopropionic acid is a convulsant which reversibly inhibits
GAD, while at the same time activating GABA-T (Johnston, 1978; Loscher,
1979).

This drug produces a rapid fall in brain GABA level.

In addi-

tion, carbonyl-trapping agents, which act as inhibitors of the coenzyme,
pyridoxal phosphate, will decrease the activity of GAD (Tapia, 1975).
Anatomy
Unlike the monoaminergic neuronal systems,

which are organized

into discrete long fiber pathways, GABA systems comprise predominantly
short-fiber
1978).

interneurons

(Fonnum,

1978;

Fonnum

and

Storm-Mathisen,

There are three principal exceptions to the "short axon rule"

for GABA neurons:

1) the striatonigral, 2) the nigrothalamic, and 3)

the pallidothalamic GABA projections (Fonnum and Storm-Mathisen, 1978).
Since the primary focus of the present work is on midbrain structures,
only the anatomy of GABA systems in the mesencephalon will be reviewed
in detail.
Substantia nigra
The

substantia nigra

contains

pmole/gram wet tissue mass (Kanazawa

the

highest concentration

[ 4. 25

et al., 1973; Balcom et al., 1975;

Fonnum and Storm-Mathisen, 1978)] of GABA in the CNS.

Within the sub-

stantia nigra there is a topographical variation in both GABA concentration and GAD activity, with the highest value for each occurring in the
medial and central parts of the pars reticulata (Tappaz

et al., 1977).
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In the pars compacta, the levels are only one-half as great.
autoradiographic

studies

have

revealed

a

In vitro

relatively high density of

binding sites for the radiolabelled GABA-receptor agonist,

3

H-muscimol,

over the substantia nigra zona reticulata, with only low densities seen
over the zona compacta (Palacios
nigra! GABA
twenty years.

and GAD has been
It

et al, 1981a; 1981b).

The origin of

investigated intensively over the past

is accepted almost universally that the substantia

nigra receives a number of GABA-ergic fibers from the corpus striatum
(Hattori et al.,
1978).

1973; Ribak et al.,

1976; Fonnum and Storm-Mathis en

Destruction of the striatonigral pathway produces a greater than

75% fall in nigra! GABA content and GAD activ.ity (Hattori
Minchin and Fonnum, 1979; Gale and Iadarola,

1980).

2E

al., 1973;

In the cat,

the

striatonigral GABA projection has been found to have a distinct topographic organization (Fonnum
putamen and posterior caudate
pars reticulata, with fibers

et al., 1974).

Briefly,

terminate mostly

fibers from the

in the posterolateral

from the head of the caudate projecting

mainly to the anteromedial region.

The fibers from the lateral part of

the caudate terminate intermediately.

Recently,

a similar pattern of

distribution has been described in the rat (DiChiara

et al., 1980).

In addition to its extrinsic GABA-ergic input, evidence has been
advanced for the existence of intrinsic GABA-ergic neurons in the pars
reticulata which project to the pars. compacta (Cheramy

et al.,

1978;

Cattabeni et al., 1979). Stimulation of the striatonigral tract enhances
the firing rate of pars compacta neurons, presumably by inhibiting inhi-
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bitory (possibly GABA·ergic) cells in the pars reticulata.
rons in the pars compacta are disinhibited (Grace
iontophoretically

applied

decreases neuronal

firing.

directly

into

the

Thus, neu-

et al., 1980). When
pars

This evidence suggests

compacta,
that there

GABA
is an

inhibitory GABA-ergic interneuron in the pars reticulata, which terminates on pars compacta neurons (DiChiara

et al., 1979a).

The substantia nigra also may be a source of GABA-ergic efferents
to other brain regions (Anderson and Yoshida, 1977; Kilpatrick
1980).

et al.,

Using a combination of retrograde and orthograde tracing techni-

ques, Clavier
projection.

et al.

(1976) have found evidence for a nigrothalamic

Intranigral administration of the excitatory glutamate ana-

logue, kainic acid, causes a marked diminution of GAD activity in the
ventromedial thalamus (DiChiara
Straugham, 1979)

et al., 1978; DiChiara et al., 1979b;

and in the superior colliculus (Di Chiara

et al.,

1979b).
Ventral tegmental

~

Certain analogies have been drawn between the nigra- striatal
dopamine system and the mesolimbic dopamine system (Fonnum and StormHathisen, 1978).
ergic input

Just as the corpus striatum receives a heavy dopamin-

from the substantia nigra

(A-9), the nucleus

together with other limbic structures, receives

accumbens,

a major dopaminergic

input from the mesencephalic ventral tegmental area of Tsai (A-10; Hoare
and Bloom, 1978).
GABA

projection

One might, therefore, expect a "limbomesencephalic"
which

is

analagous

to

the

striatonigral

pathway.
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Indeed, a high level of GAD activity has been found in the ventral tegmental area (Fonnum

et al.,

1977), and iontophoretically applied GABA

inhibits the activity of neurons in this area (Wolf

et al., 1978).

It

appears, however, that GABA-ergic inhibition in the ventral tegmental
area is mediated by local interneurons rather than a long fiber pathway,
since interruption of descending fibers from the limbic forebrain does
not alter tegmental GAD activity (Fonnum

et al., 1977).

Raphe nuclei
It is now fairly well established that GABA serves as a neurotransmitter for inhibitory interneurons within the mesencephalic B-7 and B-8
5-HT cell groups (Dahlstrom and Fuxe, 1964), which constitute the principal origin of ascending 5-HT projections to the forebrain (Azmitia and
Segal, 1978).

These 5-HT systems are thought to regulate several phy-

siological and behavioral processes (see below).

The median and dorsal

raphe nuclei are rich sources of GAD activity (Hassari
Following intracerebroventricular

administration of

3

et al., 1976).
H-GABA

into the

rat, autoradiography reveals labeled cell bodies and fibers in the dorsal raphe nucleus (Gamrani

et al., 1979). Immunocytochemical localiza-

tion of GAD supports the presence of GABA-containing cell bodies, fibers
and nerve terminals in the dorsal raphe nucleus

(Nanopoulos

et al.,

1980). Using a combination of horseradish peroxidase retrograde transport, a GAD activity measure, and

3

H-GABA autoradiographic techniques,

Belin and associates (1979) have provided evidence for a GABA system in
the midbrain periaqueductal and pontine ventricular gray, including the
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dorsal raphe nucleus (Pujol
studies have shown that

3

et al., 1981).

In vitro autoradiographic

H-muscimol binding sites are present with a

moderate density in the dorsal raphe nucleus (Palacios
1981b).

et al, 1981a;

Gallager and Aghajanian (1976), furthermore, have shown that

microiontophoretically

applied GABA produces

a picrotoxin-reversible

inhibition of the spontaneous firing of dorsal raphe 5-HT cells, which
is potentiated by both systemically and locally applied benzodiazepines
(Gallager, 1978).
Tegmental nuclei of Gudden
Among the prominent brainstem nuclei, the dorsal tegmental nucleus
of Gudden has been found to contain the highest level of GAD activity,
with the ventral
level (Massari
of
has

3

t~gmental

nucleus of Gudden having a relatively low

et al., 1976).

In addition, a moderately high density

H-muscimol binding sites over the dorsal tegmental nuclei of Gudden
been

reported

(Palacios

et

al,

1981a;

1981b).

Nauta

(1958)

included these tegmental nuclei within his limbic midbrain area because
of their interconnections with the limbic forebrain.

These areas, such

as the hippocampus and dentate gyrus, also have been shown to possess
high levels of GAD activity (Tappaz

et al., 1976).
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Neurotransmitter Role of Serotonin

---

Serotonin

(5 -hydroxytryptamine,

5 -HT),

formed

by

the

enzymatic

5-hydroxylation of !-tryptophan and the subsequent decarboxylation of
the resulting 5 -hydroxy-l-tryptophan,
transmitter
1980).

in mammalian

brain

appears to function as a neuro-

(Aghajanian

and Wang,

1978;

Fuller,

Largely confined to midbrain and hindbrain regions,

distinct

groups of 5 -HT containing perikarya first were described by Dahlstrom
and Fuxe (1964), and labeled caudorostrally B-1 through B-9.

Anatomy
Histofluorescence
(Steinbusch,

1981;

(Dahlstrom and Fuxe,

Kulmala and Lorens,

(van der Kooy and Hattori,

1964),

1982),

immunocytochemical

retrograde dye

tracing

1980b; van der Kooy and Steinbusch, 1980),

and autoradiographic (Azmitia and Segal, 1978) techniques have been used
to map out

the projections

of 5-HT neurons.

The

5 -HT

largely coincide with the brainstem raphe nuclei (Taber

cell

bodies

et al., 1960).

The more caudal B-1 through B-3 groups send axons principally to the
spinal cord and lower medulla (Lorens, 1978; Loewy and McKellar, 1981).
The B-4 through B-6 groups may provide both ascending and descending
projections (Cooper

et al., 1978; Lorens, 1978). The more rostral 5-HT

cell groups (B-7 through B-9) are the source of extensive ascending projections to the forebrain.
sal

raphe nucleus,

The B-7 cell group, which overlaps the dar-

projects

primarily

to

the

neostriatum,

tubercle, amygdala, neocortex, hypothalamus and thalamus.

olfactory

The B-8 cell

group, located predominantly in the caudal linear and median raphe nuc-
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lei, is the origin of 5-HT projections to such limbic structures as the
septum and hippocampus, as well as to the cortex, hypothalamus and substantia nigra (Azmitia and Segal, 1978; Lorens, 1978; van de Kar and
Lorens,

1979; Dray

et al.,

1976;

1978;

van der

Kooy and Hattori,

1980a).
Physiology
Serotonin appears to function primarily as an inhibitory neurotransmitter (Cooper

et al., 1978; Segal, 1981). Stimulation of the 5-HT

containing median raphe nucleus
hippocampal

neurons~

(Segal, 1975).
retically.

inhibits the spontaneous activity of

especially in the heavily innervated CA-l region

A similar effect is seen when 5-HT is applied iontopho-

Electrical stimulation of the

median raphe nucleus

also

inhibits the firing rates of medial septal neurons (Segal, 1976), whereas stimulation of the dorsal raphe nucleus inhibits neurons in the
amygdala (Wang and Aghajanian,
1975).

1977) and neostriatum (Miller

et al.,

Furthermore, perfusion in vitro with 5-HT produces a potassium-

dependent, non-chloride-dependent hyperpolarization of hippocampal CA-l
cells (Segal, 1981).
Microiontophoretically

applied 5-HT has

a

powerful and direct

inhibitory action on 5-HT neurons in the dorsal raphe nucleus (Aghajanian and Wang, 1978).

This is thought to be due to an action of 5-HT on

" autoreceptors " ·1.n t h e dorsa 1 raphe nucleus.

"Autoreceptors" may be

defined as receptors which mediate the response of a neuron to its own
transmitter.

The autoreceptors are thought to reflect the presence of
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s·HT collaterals.

Raphe cells demonstrate a very characteristic slow,

regular firing pattern

(Aghajanian and Wang,

1978).

All attempts to

"drive" these neurons antidromically have resulted in an initial rapid
burst of activity,

followed by a period of post-stimulus depression.

This is taken as physiological evidence for recurrent collateral inhibi·
tion.

Such autoregulatory mechanisms would allow raphe 5-HT cells to

maintain a tonic level of activity within a narrow range (for review,
see Aghajanian and Wang, 1978).
Pharmacology
Serotoninergic neurotransmission may be altered pharmacologically
in several different ways.

It is

clearly possible to decrease the

activity of serotonin neurons and to reduce the availability of 5·HT
post-synaptically.

It is, however, debatable as to whether it is possi·

ble pharmacologically to enhance 5-HT neurotransmission other than by
administering directly acting receptor agonists.

Drugs which enhance

the concentration of 5-HT in the synaptic cleft will lead to decreased
firing of 5-HT neurons because 5-HT will act in an inhibitory manner at
5-HT autoreceptors (Aghajanian and Wang, 1978).

Thus, drugs, whose pre-

sumed mechanism of action (such as reuptake inhibition) depends on the
release of 5-HT from axon terminals by neuronal discharge, will not lead
to an effective enhancement of 5-HT neurotransmission, because the subsequent increase in synaptic 5-HT concentration will result in negative
feedback inhibition.

By increasing the neurotransmitter concentration

at other than autoreceptor sites, serotonin releasers and reuptake inhi-
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bitors would, nevertheless, produce an acute serotoninomimetic post-synaptic response.
Serotonin receptor agonists
Receptor agonists include quipazine, bufotenin, lysergic acid diethylamide,

N,N-dimethyl-5-methoxytryptamine

and

pipamperone.

These

drugs bind to the 5-HT receptor and produce a serotonin-mimetic effect.
Quipazine has been reported to produce behavioral effects characteristic
of a 5-HT receptor agonist (Green

et al., 1976; Jacoby et al., 1976).

It would appear, however, that the apparent agonist effects of quipazine
may, in fact, be due to an antagonism of 5-HT autoreceptors (Martin and
Sanders-Bush, 1982).
··Among the indirectly acting compounds are the 5-HT reuptake inhibitors, releasers, precursors and inhibitors of degradation.
Inhibitors of 5-HT reuptake
The tertiary-amine tricyclic antidepressants (for example, imipramine) inhibit 5-HT reuptake at the presynaptic nerve terminal.

These

compounds, however, also inhibit norepinephrine reuptake to a certain
extent (Baldessarini, 1980).

Fluoxetine, zimelidine and paroxetine are

some of the more selective 5-HT reuptake inhibitors.
ever,

is metabolized

to norzimelidine,

reuptake (Fuller, 1980).

Zimelidine, how-

which inhibits

noradrenaline
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5-HT releasing agents
The drugs

,e-chloroamphetamine and fenfluramine,

in addition to

inhibiting serotonin nerve-terminal reuptake, release serotonin (as well
as norepinephrine)
Fuller, 1978).
long-term
inhibiting

from vescicular stores (Trulson and Jacobs,

1976;

These two compounds also have been reported to produce

reductions
tryptophan

in CNS serotonin
hydroxylase

concentrations,

(Sanders-Bush

and

presumably by

Steranka,

1978;

Fuller, 1980).
5-HT precursors
The

administration

of

the

5-HT

precursors,

1-tryptophan

5-hydroxy-1-tryptophan, leads to elevations in brain 5-HT level.
tunately, both of these compounds are somewhat non-specifi-c.

and

Unfor-

The essen-

tial amino acid, 1-tryptophan, is taken up by virtually all cells and
incorporated into their protein metabolism.
taken up by

catecholaminerg~c

5-Hydroxy- 1-tryptophan is

neurons, in which it can be decarboxylated

to 5-HT and released ectopically (Yunger and Harvey, 1976).
Inhibitors of 5-HT degradation
The only known inhibitors of 5-HT catabolism are the monoamine
oxidase inhibitors. None of these drugs, however, is selective for 5-HT
degradation since monoamine oxidase also is a major enzyme in the metaholism of the catecholamines (Baldessarini, 1980).
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S·HT antagonists
The

drugs which

decrease

5-HT neurotransmission are

the 5-HT

receptor antagonists, inhibitors of serotonin synthesis, and depletors
Some of the recently identified 5-HT receptor

of serotonin stores.

antagonists are cyproheptadine, methysergide, metergoline, methiothepin,
cinanserin and mianserin

(Aghajanian and Wang,

1978;

Fuller,

1980).

These drugs, however, possess varying degrees of dopamine agonist activity.

In addition, cyproheptadine is a well known histamine antagonist.

Furthermore, it is uncertain whether these agents are effective antagonists at all 5-HT receptors (see Aghajanian and Wang, 1978; Martin and
Sanders-Bush, 1982).
Inhibitors of 5-HT synthesis
The precursor enzyme in the synthesis of serotonin,
5·hydroxylase is

inhibited by

£-chlorophenylalanine.

tryptophan

The resultant

enzymatic inhibition is irreversible and thus leads to a prolonged (up
to 2 weeks) decrease in tryptophan hydroxylase activity.
nylalanine,
hydroxylase.

however,

also

inhibits

As mentioned above,

both

tyrosine

£-Chlorophe-

and phenylalanine

£-chloroamphetamine and fenfluramine

also produce long-lasting (several weeks) reductions in CNS 5-HT concentrations.

i:[I neurotoxins
The neurotoxins, 5, 6- and 5, 7 -dihydroxytryptamine, when injected
intracerebrally, either

locally or into the ventricles, destroy 5 -HT

39
containing perikarya and processes with a high degree of specificity
(Bjorklund

et

al.,

1973;

Lorens,

1978).

A secondary-amine tricyclic

antidepressant, such as desmethylimipramine, however, must be used as a
pretreatment in order to prevent the uptake of the dihydroxytryptamines
into noradrenergic neurons. 5,7-Dihydroxy- tryptamine has several advantages over 5,6-dihydroxytryptamine (see Lorens, 1978), and thus was used
in the present study.
Serotonin and Behavior
CNS 5-HT systems have been postulated as playing important roles
in several psychological and physiological processes, including temperature regulation (Hyers, 1975; 1981; Hyers and Sharpe,
Waller,

1968; Myers and

1975); modulation of luteinizing hormone, prolactin and renin

release (van de Kar

et al., 1980; 1981; Koenig et al., 1980); the res-

ponse to painful stimuli and morphine analgesia (Hessing and Lytle,
1977) and, the control of mating behavior (Karc2mar, 1980).

It is out-

side the scope of this dissertation to review all of these proposed
functions.

Thus we shall focus our comments on those behaviors which

are modified by the benzodiazepines,

possibly via an effect on the

activity of raphe 5-HT neurons.
Punished behavior
The existence of a 5-HT "punishment" system has been postulated
(Stein

et al., 1973; 1975; Haefely, 1978). If such a system exists, one

would expect pharmacological manipulation of CNS 5 -HT systems to have
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appreciable effects of punished behaviors.

The putative 5-HT receptor

antagonists,

cyproheptadine,

methysergide,

cinanserin

and

reported to produce anti-conflict effects
Sepinwall and Cook,
as

1978; 1980).

been

(Cook and Sepinwall, 1975b;

Serotonin synthesis inhibitors, such

E-chlorophenylalanine, moreover, have similar effects

Sepinwall and Cook, 1978; 1980).

have

(Koe,

1979;

Destruction of 5-HT neurons with 5,6-

and 5, 7-dihydroxytryptamine also can release punished behavior as measured in conflict tests, regardless of whether these agents are administered intracerebroventricularly (Sepinwall and Cook, 1978) or injected
directly into the ascending 5-HT pathways in the ventromedial mesencephalic tegmentum (Tye

et al., 1977; 1979).

Locomotor activity
The effects of 5-HT depletion on locomotor activity are dependent
upon the type of surgical and pharmacqlogical intervention, as well as
upon

the behavioral

paradigm employed

lesions of the median

(Lorens,

but not of the dorsal

1978).

raphe nucleus produce

hyperactivity in both a familiar (home cage; Kostowski
novel (open field; Srebro and Lorens, 1975; Hole
ment.

Electrolytic

et al, 1968) and

et al., 1976) environ-

In the open field, 5,7-dihydroxytrypt- amine lesions, in contrast

to electrolytic lesions, do not alter activity level.
lanine also fails to affect open field activity
1978), while

£-Chlorophenyla-

(Kohler and Lorens,

.E-chloroamphetamine produces a decrease in activity (for

review, see Lor ens, 19 78).

On the other hand, increases in home cage

activity have been obtained after systemic injection of the tryptophan
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hydroxylase inhibitors,

£-chlorophenylalanine and £-chloroamphetamine,

as well as following 5,7-dihydroxytryptamine lesions (Mackenzie
1978).

et al,

Recently, Williams and Azmitia (1981) microinjected different

doses (1.0 - 10

~g)

of 5,7-dihydroxytryptamine into the fornix-fimbria

which contains 5-HT fibers afferent to the hippocamus.
produced a dose-related increase in nocturnal

These injections

locomotor activity

(as

measured in photocell chambers) during the seven consecutive nights of
.testing.

A reduction of

3

H-5-HT uptake was found in the dorsal hippo-

campus and was related to the dose of 5, 7 -dihydroxytrypta- mine.
degree of dorsal hippocampal

3

The

H-5-HT uptake was negatively correlated

with the mean nocturnal activity for the seven nights of testing.

These

authors interpreted their results to imply that the increase in nocturnal locomotor activity produced by a generalized depletion of 5-HT in
the brain may be due to disruption of hippocampal 5 -HT terminals supplied by the fornix-fimbria.
It is of interest to note that bilateral electrolytic lesions in
the ventral and dorsal tegmental nuclei of Gudden which lie in close
proximity to the median and dorsal raphe nuclei, respectively, can produce increases in open field locomotor activity similar to those seen
after electrolytic raphe lesions (Lorens

et al., 1975; Lorens, 1978).

This, as well as the data alluded to above, suggests the possibility
that the effects of electrolytic raphe lesions on locomotor activity may
not be due solely to the destruction of 5-HT containing cells.

The

behavioral consequences of raphe and Gudden lesions are not, however,
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identical.

While bilateral destruction of the tegmental nuclei of Gud-

den enhances the acquisition of a two-way (shuttlebox) avoidance task,
only

combined,

not

selective,

electrolytic

dorsal and median

nucleus lesions produce a similar effect (Lorens
1978).

raphe

et al., 1975; Lorens,
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GABA-Benzodiazepine Interactions

~

In light of the potent central nervous system effects of the benzodiazepines,
receptors.

efforts have been made

to

localize CNS benzodiazepine

Recently, high -affinity, saturable, stereospecific binding

sites for benzodiazepines have been found both
al.,

1978;

Chang

and

Snyder,

1978),

and

in vivo (Williamson et
in

vitro

Braestrup, 1977; Hohler and Okada, 1977 a; Tallman

(Squires

and

et al.; 1980). The

existence of such receptors for benzodiazepines has prompted a search
for endogenous ligands.

Several substances, including the purines, ino-

sine and hypoxanthine; the cofactor, nicotinamide; a
and

a

small

peptide,

endogenous ligands.

GABA-modulin,

have

beta-carboline;

been proposed

as

possible

To date the evidence is not compelling for any one

of these substances (for a review, see Paul

et al., 1980).

Studies of the biochemical regulation of the benzodiazepine receptor

have

revealed

that

GABA

and

GABA-mimetics,

such

as

muscimol,

increase, while GABA-receptor antagonists, such as bicuculline, decrease
the affinity of benzodiazepines for their receptors

(Tallman

et al.,

1978; 1980). Moreover, permeable halide ions such as chloride and iodide,

but not

large anions

such as

citrate or sulfate,

increase the

affinity of radiolabeled benzodiazepines for their receptor (Costa

et

al., 1979). These findings suggest that the benzodiazepine receptor is
coupled. to both a GABA receptor and a chloride ionophore.

These bio-

chemical data are supported by electrophysiological observations suggesting an interaction of benzodiazepines with both a GABA receptor and
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a chloride ionophore (MacDonald and Barker, 1979; Costa
1981).

et al., 1979;

Although the morphological correlation between the distributions

of putative GABA and putative benzodiazepine binding sites

in-vitro
--

is

not perfect, there is a significant degree of overlap (see Young and
Kuhar, 1979, 1980; Palacios

et al, 1981a; 1981b).

These observations

support the hypothesis of a receptor complex in the mammalian central
nervous system which consists of a functionally coupled benzodiazepine
receptor, GABA receptor, and chloride ionophore
1979; Tallman

(Costa and Guidotti,

et al., 1980; Paul et al., 1981a; Olsen, 1982).

The benzodiazepine binding site has a truly neuromodulatory role.
The interaction of this site with its ligand produces an increase in the
affinity and/or number of GABA receptors.

The benzodiazepines depend on

the synaptic release of GABA in order to produce their physiological
effects.

In the absence of GABA, the binding of a benzodiazepine to its

receptor does
potential.

not produce any changes

in the post-synaptic membrane

It now appears that the benzodiazepines may exert many, if

not all, of their pharmacological effects (including their anxiolytic,
soporific, anti-convulsant, and muscle relaxant properties) by affecting
this system (Haefely
gaard-Larsen and Arnt,
1981; Olsen, 1982).

et al.,
1980;

1975; Costa and Guidotti,
Paul

et al.,

1981;

1979; Krogs-

Paul and Skolnick,
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Serotonin-Benzodiazepine Interactions
Benzodiazepines

exert

several

on

effects

Firstly, 5-HT synthesis and turnover rates

5-HT

are decreased.

metabolism.
Secondly,

removal of the 5-HT metabolite 5-hydroxy-3-indoleacetic acid (5-HIAA)
from the brain is inhibited.
be increased (Chase

Steady-state levels of 5-HT may or may not

et al., 1970; Koe, 1979).

A slower rate of turnover most likely represents a decrease in
5-HT release due to a reduction in the activity of serotonergic neurons.
Benzodiazepines
3

intravenous

reduce

accumulation of

H-tryptophan (Dominic

3

H-5-HT

and

3

H-5-HIAA

after

et al., 1975). They also retard the

disappearance of radiolabe1ed 5-HT following intracisternal injection of
14

C-5HT.

Interference with transport of 5-HIAA from the brain has been

inferred from the slower disappearance of labeled 5-HIAA from the brain
following
(Chase

intracisternal injection of either

et al., 1970).

14

C-5-HT or

14

C-5-HIAA

Furthermore, tolerance does not develop to the

reduction in 5-HT turnover produced by repeated daily injections of oxazepam (Wise
zodiazepines

et al., 1972; Stein et al., 1975).
to decrease 5 -HT turnover

The ability of the ben-

and to decrease serotonergic

activity in the brain may underlie several of their behavioral effects.
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Midbrain Benzodiazepine-GABA-Serotonin Interactions
As mentioned above, there is a good deal of evidence to support
the role of GABA as a neurotransmitter within the mesencephalic dorsal
and median raphe nuclei
1980; Belin

(Gamrani

et al., 1979;).

et al.,

1979;

Nanopoulos

~

al.,

Using an immunocytochemical double-label-

ing technique, Pujol and coworkers (1981) claim to have found neurons in
the dorsal raphe nucleus which contain both GAD and 5-HT.

Close exami-

nation of their data, however, reveals that the two stains are not uniformly distributed within the double-labeled cells.

Their appearance

and pattern of distribution, moreover, suggests the presence of GAD-positive terminals on 5-HT perikarya, rather than the coexistence of GAD
and 5-HT within the same cell bodies.
Young and Kuhar

(1980)

recently have demonstrated moderate to

dense benzodiazepine binding in the

periaqueductal gray,

the dorsal

raphe nucleus, the dorsal and ventral tegmental nuclei of Gudden,
the more caudally located raphe pontis and raphe magnus nuclei.
found,

and

We have

in addition, moderate benzodiazepine receptor labelling in the

region of the median raphe nucleus (Sainati

et al., 1982).

When microiontophoretically applied to spontaneously firing dorsal
raphe 5-HT cells in the rat, GABA produces a picrotoxin-reversible inhibition of spontaneous firing, which is potentiated by both systemically
and locally applied benzodiazepines (Gallager and Aghajanian, 1976; Gallager, 1978).

In addition, systemic diazepam and chlordiazepoxide have

been found to produce a dose-dependent suppression of raphe unit activ-
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itY in freely-moving cats (Preussler

et al., 1981).

Moreover, Przew-

locka and coworkers (1979) have reported that injection of muscimol into
the dorsal raphe nucleus significantly reduces 5-HT and 5-HIAA levels in
the

hypothalamus,

but

not

in the

neostriatum.

Forchetti

and Meek

(1981), furthermore, recently have examined the effects of GABA agonists
and antagonists, locally applied to the median raphe nucleus, on hippocampal 5-HT and 5-HIAA concentrations in probenecid pretreated rats.
They found that muscimol ( 100 ng) decreased 5 -HT turnover 90 minutes
post-injection, whereas picrotoxin (2.0
(2.0

~g)

not

affected.

produced opposite results.
Parenteral

~g)

and bicuculline methiodide

The hippocampal content of 5-HT was

diazepam

(

5.0

mg/kg,

intraperitoneally)

blocked the effects of the GABA antagonists and potentiated the action
of muscimol.

These results provide evidence for a tonic inhibition by

GABA neurons of the firing rate of 5 -HT perikarya in the median raphe
nucleus.
If serotonin and GABA constitute a bipole system, and as inactivation or destruction of CNS 5-HT systems produces certain specific behavioral changes (see above), then GABA-ergic inhibition of these systems
should produce similar changes.

Intracisternal administration of the

GABA-transaminase inhibitor, ethanolamine-a-sulfate, has been reported
to produce an increase in exploratory locomotor activity (File, 1977).
In addition, injection of the GABA analogue, muscimol, directly into the
dorsal raphe nuclei of ether-anesthetized rats, has been observed to
greatly increase their locomotor activity (PrzewZocka

et al.,

1979).
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These effects were antagonized by both local and systemic injections of
bicuculline and picrotoxin.
Experimental Plan
The literature reviewed above suggest that some of the clinical
and behavioral

effects of

the benzodiazepines

may be

due to

their

enhancement of GABA-ergic neurotransmission in the midbrain raphe nuclei.

The data suggest, furthermore, that benzodiazepine-enhanced GABA-

ergic inhibition of serotonergic neurons may produce striking changes in
appetitive behavior, avoidance behavior, punished behavior and locomotor
activity.

We, therefore, undertook a series of experiments designed to

investigate the extent to which GABA-ergic modulation of midbrain raphe
serotonergic neurons influences locomotor activity in the rat.
First we replicated the findings

of Przewlocka and associates

(1979) that the acute microinjection of muscimol (100 ng) into the dorsal raphe nucleus produces hyperactivity.

Secondly, we found that the

acute microinjection of muscimol (100 ng) into the median raphe nucleus
produced increases in activity which were 4 times greater than those
seen after similar injections into the dorsal raphe nucleus.

A dose-

response analysis using animals with chronically-indwelling cannulae,
and a complex Latin square design, showed that the median raphe nucleus
indeed was more sensitive to the effects of muscimol.

Thus, subsequent

experiments utilized only cannulae implanted chronically in the median
raphe nucleus.

49

To determine whether the hyperkinesis produced by the intra-raphe
injection of

muscimol was

due to

activation of

GABA receptors,

we

attempted to potentiate the effects of muscimol by administering intraperitoneally

the benzodiazepine,

chlordiazepoxide,

and

to block

the

effect with the GABA antagonist, bicuculline.
The success of these experiments prompted us to determine whether
the effects of the peripherally administered bicuculline and chlordiazepoxide were due to their binding to the same neuronal membranes as the
intra-raphe muscimol.
ments.

We thus conducted the following series of experi-

First, intra-raphe dose-response analyses for the water soluble

benzodiazepines, chlordiazepoxide, flurazepam and midazolam, were performed.

A similar study was carried out using bicuculline methiodide.

Subsequently,

animals

received

sub-effective doses

of flurazepam

or

midazolam, followed by a sub-effective dose of muscimol, into the median
raphe nucleus.

Finally, animals received a combination of bicuculline

methiodide and muscimol

into the

median raphe nucleus

whether the former drug would block the effects of the

to determine
latter.

The

results from these experiments supported the view that the intra-raphe
injection of muscimol produces hyperkinesis via an activation of local
GABA receptors.
Since destruction of the ventral tegmental nuclei of Gudden produces hyperactivity, and since these nuclei have been reported to contain a high density of benzodiazepine receptors,

we investigated the

effect such lesions on the intra-raphe muscimol dose-response relation-
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shiP·

To ascertain the role of ascending 5-HT systems in the mediation

of the hyperkinetic effect of intra-raphe muscimol, we examined the mus·
cimol

dose-response

relationship

following

5, 7 -dihydroxytryptamine

induced degeneration of these projections.
The results obtained from these experiments,

overall,

strongly

suggest that the activation of midbrain GABA receptors produces a hyperkinetic response in rats which depends on the integrity of an ascending
serotonin system for its expression.

CHAPTER II

MATERIALS AND METHODS
Animals
The experimental subjects were male Sprague-Dawley rats (King Animal Farms, Orange, WI), 90 - 120 days old and weighing 310 - 375 grams
at the time of surgery.

The animals were housed individually in a temp-

erature (22 +/- l°C), humidity (40 - 52%), and illumination (12 hour
light-dark cycle) controlled room.

Food and water were available

ad

libitum in the home cage.
Surgery
A Kopf stereotaxic instrument was used. The incisor bar was set
3.2 mm above the interaural plane.

,

At the time of surgery, each animal

received 50 mg/kg ampicillin (Omnipen-N, Wyeth) and 0.4 mg/kg atropine
sulfate (Lilly), intramuscularly, and chloramphenicol (Chloromycetin, 1%
ophthalmic ointment; Parke-Davis) topically around the wound.

For the

acute intra-raphe microinjections, ether (Malinckrodt) was employed as
an anesthetic,

and the wound margins were infiltrated with 0.1 ml of

lidocaine hydrochloride (Xylocaine; Astra, Worcester, MA) in order to
minimize post-operative pain.

For other surgical procedures intraperi-

toneal pentobarbital sodium (SO mg/kg; Butler, Columbus, OH) was used as
an anesthetic.

All wounds were closed with autoclips (Clay Adams).
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Acute Intra-Raphe Injections
Muscimol (100 ng in 0. 5

)ll

of vehicle) or saline (0. 5 J.ll) was

administered via a 5.0 ul Hamilton syringe with a 30-gauge needle (0.35
mm o.d.) oriented mid-sagittally at an angle of 47° caudal to the vertical plane.

The solution was delivered slowly (in about 60 seconds). The

needle was left
tion.

in situ for 2 min following completion of the injec-

Coordinates for the dorsal raphe placement were 6.2 mm caudal and

9.6 mm ventral to the skull surface 1.0 mm rostral to lambda (L + 1).
Coordinates for the median raphe placement were 8.1 mm caudal and 12.1
mm ventral to L + 1.
Chronic Intra-Raphe Cannula Placement
A guide cannula (0.46 mm o.d. and 0.25 mm i.d.; Plastic Products
Co., Roanoke, VA) was implanted in either the dorsal or the median raphe
nucleus.

A stylet (0.23 mm dia) then was inserted such that its tip was

flush with that of the guide cannula.

This assembly then was cemented

onto stainless steel anchoring screws embedded in the skull.

The coor-

dinates were the same as mentioned above.
Electrolytic Lesions
A 0.25 mm diameter stainless steel wire insulated with Expoylite
except at the cross section of its tip was used as the lesion electrode.
This

electrode was connected to the positive pole of a Grass model

DCLM-5A direct current lesion maker
Quincy, MA).

(Grass Medical Instruments Co.,

An alligator clip attached to the wound margin served as
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the ground.

Lesions were produced bilaterally in the ventral tegmental

nuclei of Gudden (VTG) by passing 2.0 milliamperes direct current for 2
seconds via the anode.

The anode was inserted stereotactically at an

angle 47° caudal to the vertical plane.

The coordinates used were 0.5

mm lateral to the midsagittal suture, and 7.5 mm caudal and 11.7 mm ventral to the skull surface at L + 1.
Neurotoxic Lesions
The specific serotonin neurotoxin, 5,7-dihydroxy- tryptamine creatinine sulfate (5,7-DHT; Sigma Chemical Co., St. Louis, MO), was dissolved in 0. 2% ascorbate in 0. 9% saline, and was injected bilaterally
either into the lateral cerebral ventricles (75

~g

free base in 5.0 pl

vehicle), or into the ventromedial mesencephalic tegmentum (4.0 pg base
in 2.0 pl) at a rate of 0.5 pl/minute.

The coordinates used were 0.5 mm

rostral to bregma, 1.2 mm lateral to the midline, and 5.5 mm ventral to
the skull surface for the lateral ventricle injections; and, an angle of
47°

caudal to the vertical plane, 5.5 mm caudal to

lambda,

0.6 mm

lateral to the midline, and 11.0 mm ventral to the reading at lambda for
the mesencephalic tegmentum injections.
desmethylimipramine hydrochloride

These subjects all received

(Merrell, Cincinnati,

intraperitoneally, 30 - 45 minutes prior to surgery.

OH), 20 mg/kg

Because desmethy-

limipramine potentiates the anesthetic effects of pentobarbital,
dose of the anesthetic for these animals was 35 mg/kg.

the
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Drugs
Intraperitoneal Administration
Chlordiazepoxide hydrochloride (Roche, Nutley, NJ) was dissolved
in 0.9% saline to final concentrations (as the base) of 3.1, 6.3, 12.5,
25.0

and

50.0

umole/ml

(0.9,

1.9,

3.8,

7.5

and

15.0

(+)-Bicuculline (Sigma) was dissolved in acidified vehicle (pH

mg/ml).

= 5.5

-

6.0) to final concentrations of 0.19, 0.38, 0.75, 1.50 and 3.00 umole/ml
(0.04, 0.07, 0.14, 0.27, 0.55 and 1.10 mg/ml).
Intracranial Administration
All drugs injected intracranially were dissolved in 0.9% saline.
Muscimol (Sigma) was prepared in concentrations of 0.22, 0.44, 0.88,
1.75 and 3.50 nmole/ 0.5 pl (25, 50, 100, 200 and 400 ng/ 0.5 p.l).
Bicuculline methiodide (Pierce Chemical Co., Rockford, IL) was prepared
in concentrations (as the base) of 0. 22, 0. 44 and 0. 88 nmole/ 0. 5 )ll
(81, 161 and 323 ng/ 0.5 pl).

Chlordiazepoxide hydrochloride (Roche),

flurazepam dihydrochloride (Roche), and midazolam maleate (Roche) were
prepared in concentrations of 0.11, 0.22, 0.44, 0.88 and 1.75 nmole/ 0.5
ul.

These concentrations, expressed in terms of mass (of the base),

are:

chlordiazepoxide - 44, 88, 175, 350 and 700 ng; flurazepam - 43,

85, 170, 340 and 680 ng; and midazolam - 36, 71, 143, 286 and 571 rig.
Biochemical Analysis
The animals were killed by decapitation and their brains quickly
removed and dissected on a glass plate over dry ice as described by Lor-
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ens and Guldberg (1974).
aluminum foil,

The hippocampi and striata were wrapped in

flash frozen in liquid nitrogen, and stored in a -70°C

freezer for no more than 3 weeks prior to assay.

The brainstems were

placed in phosphate-buffered formalin and fixed for at least 2 weeks
prior to sectioning.
Serotonin (5-HT) and 5-hydroxy-3-indoleacetic acid (5-HIAA) levels
were determined by high-performance liquid chromatography (HPLC; Hefford, 1981).
0.1

Each tissue sample was sonicated for 20 sec in 500 ul of

!:! perchloric acid which contained 1. 0

thioglyoxylic

acid,

and

thyl-5-hydroxytryptamine
15,000 x

~

50

~g

(NHSHT).

of

the

m~

sodium EDTA, 0. 3 mH

internal

standard,

The homogenate wa:s

N-me-

centrifuged at

for 10 min, then microfiltered by centrifugation using mil-

lipore tubes.

The filtrate was drawn into a six port rotary valve

(Rheodyne Hodel No.

7125) and injected into an HPLC system (BioAnalyti-

cal Systems, Inc., West Lafayette, IN) utilizing a reverse phase column
(lOJ.lm

C-18, Waters Associates, Milford,

~-Bondapak

Model No. M-45 pump.
cetic acid, 10
was 1.5 ml/min.

m~

MA) and a Waters

The mobile phase consisted of 0.15

octanylsulfonic acid and 1.0

mM EDTA.

M monochloroaThe flow rate

Electrochemical detection was accomplished with an LC-4

amperometer (BioAnalytical Systems).

Retention times were:

24.8 min, 5-HT - 29.8 min, and NM5HT - 32.3 min.

5-HIAA -
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Histology
Those animals not requiring biochemical determinations of 5-HT and
5-HIAA levels were perfused transcardially with 100 ml of saline followed by 100 ml of phosphate-buffered formalin.

Their brains then were

removed and post-fixed for at least one week prior to sectioning.

After

the tissue was well fixed, it was transferred to a solution containing
5% sucrpse in 0.1

M phosphate buffer for 24 - 48 hours.

The tissue

then was frozen with dry ice and cut on a sliding microtome.

Every

fourth section (SO pm) was retained, mounted on a gelatin coated slide
and stained using the cresylecht violet procedure

(Powers and Clark,

1955) .
Apparatus
Activity

level was

measured in enclosed cylindrical photocell

chambers (46 em dia x 42 em high; Model No. PAC-001, Lehigh Valley Electronics, Inc., Beltsville, MD) with wire mesh floors.

The interiors of

the walls and covers of these chambers were painted flat black.

Inter-

ruption by the animal of any one of six photocell beams located at the
base of the chamber activated an electromechanical counter.
Statistical Analysis
The data from Experiment II were analyzed using a complex Latin
square design (Bruning and Kintz, 1977, pp. 92-106).

Data from Experi-

ments III and IV were analyzed using an analysis of variance (ANOVA)
with a repeated measures -two factors design

(ibid, pp.

48-54).

The
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data from the biochemical and the remaining behavioral experiments were
analyzed by an ANOVA, two-factor mixed design with repeated measures on
one factor

(ibid, pp. 55-61); and, a three-factor mixed design with

repeated measures on two factors (Kirk, 1968; Bruning and Kintz, 1977,
pp. 73-84).
merited,

Individual between-group comparisons were performed, when

by Newman-Keuls'

multiple range

test

(Newman,

1939;

Keuls,

1952; Bruning and Kintz, 1977, pp. 119-122), or by an F-test. for simple
effects

(ibid, pp. 140-142).

For within group comparisons, a Newman-

Keuls test for related measures (Keuls, 1952; Bruning and Kintz, 1977,
pp. 137-138) was used.

Statistical analyses were performed on a Hew-

lett-Packard HP-85 minicomputer with a No.

90053 statistical program

package, as well as with Nos. 300-0027, 300-0029, 300-0035 and 300-0043
ANOVA programs (Hewlitt-Packard Corp., Corvallis, OR).

CHAPTER III

RESULTS
Experiment I
ACUTE INTRA·MIDBRAIN MICROINJECTIONS OF MUSCIMOL
It has been reported (Przewlocka

et al., 1979) that acute injec-

tions of muscimol (50 and 100 ng) into the dorsal raphe (DR) nucleus of
rats produce elevations in locomotor activity.
we attempted to replicate these findings.

In our first experiment,

In addition, the effects of

muscimol injections into the DR were compared to those following injections into the median raphe nucleus (MR).
Procedure
Rats were anesthetized with ether and injected with muscimol (100
ng in 0.5

~1

the MR (n

= 7)

ter II).

of saline) or saline (0.5 pl) into either the DR (n

= 7)

or

as described in the Materials and Methods section (Chap-

Four additional animals

served as

sham-operated controls.

These animals were treated in the same manner as the injected rats,
except that a needle was not lowered into their brains.
post-injection,

the rats,

fully awake,

Fifteen minutes

were placed in the photocell

chambers, and their activity counts recorded every 15 minutes for 90
minutes.
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Results

His~ological

analysis

Of the 7 animals which received muscimol injections into the MR,
one was eliminated from the study prior to analysis of the behavioral
data because the needle tract terminated 1.5 mm laterally in the mesencephalic reticular formation.
in 4

terminated in the

Of the remaining animals, the needle tips

rostral extent of

the B-8 5-HT

cell group

(Dahlstrom and Fuxe, 1964; Steinbusch, 1981; Kulmala and Lorens, 1982)
just dorsal to the rostral one-third of the interpeduncular nucleus.
The needle tips in the other 2 rats were localized in the MR at the
level of the ventral tegmental nucleus of Gudden (Figure 3).

The needle

tips of the 3 animals which received vehicle injections into the MR were
similarly placed at the level of the ventral tegmental nucleus of Gudden.
Of the 7 animals which received muscimol injections into the DR,
one was rejected from further analysis because the needle tip was localized within the lumen of the cerebral aqueduct.

In the remaining ani-

mals, the needle tips terminated in the rostral DR at the level of the
third and fourth cranial nerve nuclei (Figure 4).

The animals which

received vehicle injections into the DR had similar needle placements.
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Figure 3:

Photomicrograph of median raphe (MR) needle tip.

Cresylecht violet stained coronal
the

caudal

midbrain

Experiment I.

The

of

a

section (50 J.lm)

MR-muscimol

needle tip

injected

(black arrow)

small cavity rimmed by a glial scar, and,

through
rat

from

appears

as a

in this

animal,

terminates in the caudal portion of the B-8 5-HT cell group
at

the

level

Abbreviations:

of

the

VTG.

Aq = cerebral

Bar

represents

aqueduct of

Sylvius;

1

mm.
IPN =

interpeduncular nucleus; ML =median lemniscus; MLF =medial
longitudinal fasciculus; VTG = ventral tegmental nucleus of
Gudden.
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Figure 4:

Photomicrograph of dorsal raphe (DR) needle tip.

Nissl stained coronal section (50 pm) through the midbrain
of a DR-muscimol injected rat from Experiment I.
tip (black arrow) appears
glial

reaction,

and,

in

The needle

as a small cavity rimmed by a
this

animal,

terminates

in

the

rostral part of the B-7 5-HT cell group at the level of en
IV.

Bar represents

1 nun.

Abbreviations:

Aq = cerebral

aqueduct of Sylvius; en IV= trochlear nucleus.
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Activity level
An ANOVA of the number of counts per 15 minutes failed to demonstrate any significant differences between the 4 sham-operated, the 3
MR-vehicle

injected,

and

the

3 DR-vehicle injected

animals.

groups, therefore, were combined into a single control group.

These
Subse-

quently an ANOVA revealed significant treatment [F(2,20)=23.3, p<O.OOl],
time [F(14,140)=13.4, p<O.OOl], and interaction [F(14,140)=7.6, p<O.OOl]
effects between the control and muscimol injected groups.

The cumula-

tive activity scores per 15 minutes for each group are shown in Figure

~

Between-group comparisons of the total 90 minute activity scores
showed that both the MR- and DR-muscimol injected groups were significantly more active than the. control group.

The MR-muscimol injected

group, furthermore, was significantly more active than the DR-muscimol
injected group.
Individual group comparisons of the activity scores for each 15
minute period (Figure 5) revealed that the MR-muscimol injected group
was significantly more active during the first 15 minutes in the apparatus and throughout the remainder of the 90 minute test session. The
activity level of the DR-muscimol injected group did not differ from
control during the first 15 minute segment, but was significantly higher
than control for the remainder of the test session.

The hyperactivity

induced by muscimol injections into the MR, thus, was more rapid in
onset and of a greater magnitude, than that produced by the DR-muscimol
injections.

In fact, at the end of the 90 minute session, the cumula-
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tive activity scores of the MR-muscimol injected group was approximately
four times greater than that of the DR-muscimol injected group.
Conclusion
In this first experiment we were able to confirm the report of
Przewlocka

et al. (1979) that muscimol injections into the DR produce

hyperactivity.

In addition, we found that muscimol injections into the

MR also produced a hyperkinetic effect, and, that this effect not only
appears earlier after injection, but is of a much greater magnitude.
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Figure 5:

Activity scores after acute muscimol injection.

Group (Mean +/- S.E.M.) cumulative activity scores in rats

= 10)
(MR, n =

following acute microinjection of vehicle (control, n
or muscimol into the dorsal (DR, n

= 6)

,

or median

6) raphe nucleus.

>':

significantly different from control group (p<O. 01);

1" significantly different from DR-muscimol injected group

(p<O.Ol, Newman-Keuls' multiple range test).
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Experiment g
MUSCH10L DOSE-RESPONSE RELATIONSHIP IN ANIMALS
WITH CHRONICALLY INDWELLING CANNULAE

In order

to rule

out the

possible interactions

of the

ether

anesthesia and the acute surgical trauma with the effects of intra-midbrain muscimol injections on locomotor activity, we performed a doseresponse analysis using animals having cannulae chronically implanted in
the DR or the MR.

Furthermore, since each animal served as

trol and received each drug dose,

it~

own con-

a complex Latin square design was

employed in order to determine whether a given dose schedule produced
effects significantly different from another.
Procedure
Beginning 1 week post-operatively, the animals were adapted to the
test apparatus and injection procedure (Jacquet, 1975) for 3 consecutive
days (\vednesday - Friday).

The subjects were placed in the photocell

chambers for 30 minutes, removed and wrapped in a towel for 30 - 60 seconds, then returned to the chambers for an additional 2 hours.

During

the subsequent three weeks, the animals were tested Monday through Friday,

muscimol or vehicle injections being performed on Tuesdays and

Thursdays.

The animals were placed in the apparatus for 30 minutes and

their activity scores recorded for each 15 minute segment.

The rats

then were removed, wrapped in a towel, and injected (on drug days only)
over 30 seconds with 0. 5 1-11 of drug solution.

The animals then were

placed back in the chambers for an additional 2 hours.

Activity counts
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were recorded 15, 30, 60, 90 and 120 minutes post-injection.
(0, 25, 50, 100, 200 and 400 ng in 0.5

Muscimol

saline) was injected into the

~1

MR or the DR according to a complex Latin square design (Bruning and
Kintz, 1977, pp. 92 - 106), with at least 10 animals receiving each of
the 6 dose sequences.
Results

Histological analysis
Prior to performing any statistical analyses of the behavioral
data, we screened the cannula placements.

Of the 60 animals implanted

with MR cannulae, 30 were found acceptable.

The cannulae in these ani-

mals terminated within the B-8 5-HT cell group coinciding with the caudal linear and median raphe nuclei, just dorsal to the interpeduncular
nucleus.

The histological appearance of the cannula placements in these

animals was similar to the needle tracts obtained in Experiment I (see
Figure 3).

The cannula tips of the rats rejected from the study termi-

nated at least 1. 5 mm lateral, dorsal, and/or caudal to the B-8 5 -HT
perikarya.
Of the 72 rats which were implanted with DR cannulae, only 30 had
acceptable placements.

The cannula tips

in these animals

all were

localized within the boundaries of the DR (B-7 5-HT cell group).

The

cannulae in the animals eliminated from the study terminated at least
0.75 mm dorsal and/or lateral to the DR.

The histological appearance of

the DR cannula tracts was indistinguishable from that of the DR needle
tracts obtained in Experiment I (see Figure 4).
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Activity level
An ANOVA of the activity scores per 15 minutes for the 30 minute
pre-drug session on each of the 6 drug days showed that there were no
significant cannula placement, days, or interaction effects.

There was

a significant time effect [F(1,58)=63.20, p<0.001] due to the greater
activity of the animals during the first 15 minutes of the 30 minute
pre-drug period.

These results show that the animals' activity levels

were comparable during the pre-drug sessions on each of the 6 drug days.
Subsequently, a complex Latin square analysis of the total 120 minute
post-injection activity scores was performed. This analysis revealed a
significant overall effect of placement site [F(1,48)=5.04, p<0.05], a
significant

overall

effect

of

the

muscimol

dose

[F(5,240)=29.08,

p<0.0001], and a significant interaction between dose and injection site
[F(5,240)=22.21, p<0.0001].

Importantly, the effects of order of treat-

ment were not significant.
As shown in Figure 6, injections of muscimol (50 - 400 ng) into
the MR produced significant increases in activity.
seen after the 100 ng dose.

The peak effect was

In contrast, only the two highest doses of

muscimol (200 and 400 ng) induced hyperactivity following injection into
the DR.

The temporal effects of intraraphe muscimol

shown in Figure l

inj actions

are

For clarity, only the data are presented which were

obtained following the saline injections and following the doses of muscimol which produced optimal effects (Figure 6)
either the MR (100 ng) and DR (200 ng).

after injection into

The muscimol-induced hyper-
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Figure 6:
Total

Dose-activity effects of intra-raphe muscimol.

activity

period

scores

following

(Mean +j-

muscimol

S.E.M.)

injections

for
via

the

2 hour

chronically

indwelling

median (MR, n = 30) or dorsal (DR, n = 30) raphe

cannulae.

The

muscimol

was

administered

Latin square design with 5 animals

according

receiving

to

a

each of the

dose sequences.

•':

significantly

higher

than

control

condition

(p<O.Ol,

Newman-Keul's multiple range test);

t significantly higher than OR-injected group (p<O.OOOl),

# significantly higher than MR-injected group (p<O.OOOl, Ftest for simple effects).
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Figure 7:

Temporal effects of intra-raphe muscimol
injections.

Cumulative activity scores (Mean +j-S.E.M.) 15, 30, 60, 90
and 120 minutes following the injection of opitmal doses of
muscimol

through

cannulae

chronically

implanted

in

the

median (MR - 100 ng, n = 30) or the dorsal (DR - 200 ng, n =
30) raphe nucleus.

The MR- and DR-saline scores were those

obtained following saline (0.5) pl injections.

*

significantly elevated over corresponding saline-injected

control condition

(p<O. 01, Newman-Keuls'

test for

related

measures);
t

significantly elevated over DR-muscimol (200 ng) injected

condition (p<O.OS, Newman-Keuls' multiple range test).
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activity was most prominent during the first 30 minutes post-injection,
and diminished in magnitude over the subsequent 90 minutes.
Conclusion
These observations indicate that injection of muscimol into the MR
produces a significant elevation in activity level at a dose (SO ng)
one-fourth that required to produce a similar effect when injected into
the DR.

The magnitude of the hyperkinetic effect following the injec-

tion of an optimal (100 ng) dose of muscimol into the MR, moreover, is
at least 1.5 times greater than after such an injection of an optimal
dose (200 - 400 ng) into the DR.

These results suggest the possibility

that the hyperkinetic effect of muscimol following injection into the DR
may be due to diffusion of the drug to an effective MR site.
Inasmuch as the MR proved to be more sensitive to muscimol than
the DR, we decided to concentrate our subsequent efforts on the MR site.
Furthermore, since we found in Experiment II that

~he

order of adminis-

tration of the drug treatments did not significantly affect the experimental outcome, we also decided to employ the more cost-effective randomized block designs (Kirk, 1968) in our subsequent experiments.
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Experiment III
INTERACTIONS OF PERIPHERAL BICUCULLINE AND CHLORDIAZEPOXIDE
WITH INTRA-RAPHE INJECTIONS OF MUSCIMOL
In the previous two experiments

it was shown that intra-raphe

injections of muscimol produce hyperactivity as measured in photocell
chambers.

If the hyperkinetic effect of muscimol is due to the activa-

tion of GABA receptors, then this effect should be attenuated by the
peripheral administration of the GABA receptor antagonist, bicuculline,
and potentiated by the facilitator
chlordiazepoxide.

of GABA-ergic neurotransmission,

It was the objective of the present experiment to

test these hypotheses.
In a preliminary study (Sainati and Lorens, 1981) we determined
that

chlordiazepoxide,

when

administered

intraperitoneally

in doses

greater than 3.8 mg/kg produced decreases in locomotor activity as mea-

,

sured in dark photocell chambers.
appeared ataxic and sedated.

Following these doses, the animals

Doses ranging between 1.2 - 3.8 mg/kg

not affect activity as compared to control.

did

We also found that the

intraperitoneal injection of bicuculline in doses ranging between 0.1 1.1 mg/kg had no effect on activity level.

Higher doses regularly pro-

duced seizures, the convulsant dose for 50 percent of the cases (ED-50)
being 2.2 mg/kg.

In the following experiment, therefore, the 3.8 mg/kg

dose of chlordiazepoxide, and the 1. 1 mg/kg dose of bicuculline were
used.
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Procedure
Cannulae were implanted in the MR of 18 animals as described in
the Materials and Methods section (Chapter II).

Groups of 9 rats each

were assigned to the studies of the chlordiazepoxide-muscimol interaction, and of the bicuculline-muscimol interaction.

The testing proce-

dure was identical to that described in Experiment II, except that the
activity counts were recorded every 15 minutes for only one hour postinjection.
Fifteen minutes prior to receiving muscimol

(0,

or 50 ng)

25,

injections into the MR, one group of rats received either saline (1.0
ml/kg)

or

chlordiazepoxide

(3.8

mg/kg)

intraperitoneally.

Fifteen

minutes prior to receiving intra-raphe muscimol (0, 50, or 100 ng), the
other group of rats received either the acidified vehicle (1.0 ml/kg) or
(+)-bicuculline (1.1 mg/kg) intraperitoneally.
A repeated measures - two factors ANOVA design was used in the

statistical analysis of the behavioral data.

This is an analysis which

can be used when all treatments in a two-factor experiment are administered to each subject (Bruning and Kintz, 1977, pp. 48-54).
of each treatment can be discerned individually,
between· the two can be ascertained.

The effects

and the interaction

Because no statistical test for

simple effects exists specifically for the repeated measures - two factors ANOVA design, individual comparisons between means were made with
Studnet's t-test for related measures (Student, 1927; Bruning and Kintz,
1977, pp. 13-16).
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Results

Histological analysis
Two rats were eliminated from the chlordiazepoxide-muscimol study
and one rat was eliminated from the bicuculline-muscimol study prior to
statistical analysis of the behavioral data, since the cannula placements in these animals were localized 1. 5 mm lateral to the MR.

The

cannula tips in the accepted animals terminated in the B-8 5-HT cell
group dorsal to the interpeduncular nucleus.
Locomotor activity
Chlordiazepoxide-Muscimol Interaction.

An ANOVA of the total 60

minute post-injection activity scores failed to demonstrate a significant effect of chlordiazepoxide alone.

The effect of muscimol, however,

was significant [F(2,16)=7.37, p<O.Ol], as was the muscimol- chlordiazepoxide interaction [F(2,16)=6.30, p<O.Ol].

Thus, as shown in Figure

8, the parenteral injection of chlordiazepoxide potentiated the effect
of intra-raphe muscimol (25 and 50 ng) on locomotor activity.
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Figure 8:

Chlordiazepoxide potentiates the muscimol effect.

Total activity sc.ores

(Mean +/- S.E.H.)

for

the one hour

period following the injection of muscimol (0, 25 or 50 ng)
into
prior

the
to

median raphe

nucleus

receiving muscimol,

chlordiazepoxide

(3. 8

(n = 7).
the

mg/kg)

or

than

the

animals

Fifteen minutes
received

saline

either

(1. 0

ml/kg)

corresponding

control

intraperitoneally.

,-:

significantly

greater

condition (p<O.Ol);

1

significantly higher than the corresponding saline plus

muscimol effect (p<O.OS, Students t-test, 2-tailed).
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Bicuculline-Muscimol Interaction.

An ANOVA of the total 60-minute

post-injection activity scores failed to show a significant effect of
bicuculline by itself.

However, the effect of muscimol was significant

[F(2,16)=8.64, p<0.005], as was the bicuculline - muscimol interaction
[F(2,16)=6.69,

p<0.05].

hyperkinetic effect of

Figure

9

depicts

intra-raphe muscimol

the
(50

blockade

and

100 ng)

of

the

by the

peripheral administration of bicuculline.

Conclusion
These results support

the view that the hyperkinetic effect of

intra-raphe muscimol injection is due to an activation of GABA receptors.
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Figure 9:

Bicuculline blocks the muscimol effect.

Total activity scores

(Mean +/- S.E.M.)

for

period following injection of muscimol (0,
into
prior

the median raphe nucleus
to

receiving

bicuculline

(1.1

muscimol

mg/kg)

(n = 8).

the

animals

the one hour

50,

or 100 ng)

Fifteen minutes
received

or acidified vehicle

(1.0

either
ml/kg)

intraperitoneally.

'" significantly higher than corresponding vehicle-injected
control condition (p<0.01);

t

significantly

lower

than

corresponding

vehicle

muscimol effect (p<0.002, Student's t-test, 2-tailed).

plus
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Experiment IV
In Experiment III it was shown that the peripheral injection of
chlordiazepoxide potentiated,
bicuculline blocked,

whereas the systemic

administration of

the hyperactive effect of intra-raphe muscimol.

These data support the view that the hyperkinetic effect of intra-raphe
muscimol is due to the activation of GABA receptors.

However, since

GABA and benzodiazepine receptors are localized throughout the neuraxis,
we cannot be certain that the effects of bicuculline and chlordiazepoxide are due to their binding allosterically to the same GABA receptors
as those occupied following the intra-raphe injection of muscimol.
order

to determine whether the

effects of

In

peripherally-administered

bicuculline and chlordiazepoxide are due to their interaction with muscimol at the same receptor sites, we performed the following series of
experiments:

a) an intra-raphe benzodiazepine dose-response analysis;

b) an intra-raphe bicuculline dose-response analysis; c) a test of the
interactions between intra-raphe benzodiazepines and muscimol; and, d) a
test of the interactions between intra-raphe bicuculline methiodide and
muscimol.
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IVa:
INTRA-RAPHE BENZODIAZEPINE DOSE-RESPONSE ANALYSIS
There is a substantial amount of evidence which indicates that
GABA serves as a neurotransmitter in both the DR (Gallager, 1978; Nanopoulos

~

al., 1980) and the MR (Forchetti and Meek, 1981).

The benzo-

diazepines, moreover, are thought to act by facilitating GABA-ergic neurotransmission

(Gallager,

1978;

Costa

and

Guidotti,

1979).

We

hypothesized, therefore, that intra-raphe injections of benzodiazepines
also should produce hyperactivity by facilitating the effects of endogenously released GABA.
Procedure
Three water soluble benzodiazepines (chlordiazepoxide, midazolam
and

flurazepam) were

chosen for

intra-raphe dose-response

analysis.

Cannulae were implanted in the MR of 18 rats as described in the Materials and Methods section (Chapter II).

Six of the rats were assigned to

the chlordiazepoxide group, six to the midazolam group, and six to the
flurazepam group.
in Experiment II.

The subjects were tested using the same procedure as
Activity counts were recorded 15 and 30 minutes

before and 15, 30, 60, 90 and 120 minutes after injection.

On drug

days, animals received saline or a dose of the appropriate benzodiazepine (0, 0.22, 0.44, 0.88 or 1.75 nmole).
ANOVA with repeated measures on two factors

A three-factor split-plot
(Kirk,

1968; Bruning and

Kintz, 1977, pp. 73-88) was used to analyze the results of this experiment.
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Results

Histological analysis
The behavioral data from 2 rats (one from the chlordiazepoxide
group and one from the midazolam group) were eliminated prior to statistical analysis, since the cannula tips in these animals were localized
1.0 - 2.0 mm lateral to the MR.

The cannula tips in the accepted ani-

mals terminated in the rostral portion of the B-8 5-HT cell group, dorsal to the interpeduncular nucleus.
Locomotor activity
An ANOVA of the behavioral data demonstrated differences in the

response to the three drugs [F(2,15)= 20.25, p<0.0002].

The effects of

the

[F(5,75)=13.79,

different

p<O. 0001].

drug

doses

The subjects'

after injection.

also

were

significant

performances changed as a function of time

[F(3,45)=668.26, p<0.00001].

In addition, the drug

and dose [F(10,75)=4.08, p<0.0005], the drug and time [F(6,45)=31.19,
p<O.OOOl], the dose and time [F(15,225)=7.64, p<0.0001], and the drug,
dose and time [F(30,225)=4.01, p<0.0001] interactions all were significant.

Individual comparisons demonstrated that injections of flurazepam

and midazolam into the MR produced a dose-dependent elevation in locomotor activity (Figure 10).

Flurazepam was· twice as potent as midazolam,

the former having a peak effect at 0.44 nmole, the latter at 0.88 nmole.
Chlordiazepoxide was without effect.

As shown in Figure 11, the benzo-

diazepine-induced hyperactivity was most prominent during the first 30
minutes post-injection.
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Figure 10:
Total activity

Intra-raphe benzodiazepine dose-response
relationship.
scores

(Mean +/-

S.E.M.)

for

period following injection of 0, 0.22, 0.44,
nmole of flurazepam (FLU; n

= 6),

the

2 hour

0.88 or 1. 75

midazolam (MID; n

= 5)

or

chlordiazepoxide (CDP; n = 5) through cannulae chronically
implanted in the median raphe (MR) nucleus.
Asterisks

indicate

significant

elevation

over

the

corresponding saline-injected control (dose = 0) condition
('"'p<0.05, '"''•p<O.Ol, Newman-Keuls' multiple range test).
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Figure 11:

Temporal effects of intra-raphe benzodiazepines.

Cumulative activity scores (Mean+/- S.E.M.)

15, 30, 60, 90

and 120 minutes following the injection of optimal doses of
flurazepam (FLU, 0.44 nmole); midazolam (MID,
or

chlordiazepoxide

(CDP,

0.44

nmole)

0.88 nmole);

through

cannulae

chronically implanted in the median raphe nucleus.

For the

sake of clarity, the post-saline control (CONT.)

scores for

the 3 groups have been combined.

;b':

significantly

elevated

over

the

corresponding

saline-

injected control condition (p<O.Ol, Newman-Keuls' test for
related measures).
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Conclusion
Facilitation of midbrain GABA neurotransmission by
tions

of

the

benzodiazepines,

increase in locomotor activity.

flurazepam and

intra-~ffi

midazolam,

led

injecto

an

Although qualitatively similar to the

effects of intra-MR muscimol, the magnitude and duration of the benzodiazepine effects were somewhat less.
since the

effects of

This is not surprising, however,

the benzodiazepines

depend on

the release

endogenous GABA, whereas muscimol, as a receptor agonist, does not.

of
The

effective pharmacological doses of muscimol no doubt produce a greater
concentration of receptor ligand than does the amount of GABA normally
available for release.
Interestingly, in contrast to midazolam and flurazepam, chlordiazepoxide failed to alter activity level following its injection into the
HR.

This observation supports the view that chlordiazepoxide is a pro~

drug, similar to prazepam and chlorazepate, which must be oxidized

in

vivo to produce a centrally active metabolite (Johnson and Rising, 1980;
Breimer

et al., 1980).

tory (Sainati
that
3

both

Recent autoradiographic studies in our labora-

et al., 1982) support this conclusion.
midazolam

and

flurazepam

displaced

H-flunitrazepam from brain stem tissue sections

poxide, however,

failed to do so.

Briefly, we found
the

in vitro.
----

binding

of

Chlordiaze-

It would appear, therefore,

that

chlordiazepoxide itself is not active at CNS benzodiazepine receptor
sites.
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IVb:

INTRA-RAPHE BICUCULLINE DOSE-RESPONSE ANALYSIS
Procedure
Because the free base form of bicuculline must be dissolved in a
vehicle too acidic for direct intracranial injections, this experiment
was

performed

with

the water-soluble

salt,

bicuculline methiodide.

Seven rats were outfitted with chronically indwelling cannulae in the
MR.

Animals were tested· as described in the procedure for Experiment

II.

On drug days, subjects received intracranial injections of either

saline or bicuculline methiodide (0.22, 0.44 or 0.88 nmole; 81, 161 or
323 ng as the base) according to a randomized block design.
Results

Histological analysis
Of the 7 rats tested, only 5 were found to have acceptable cannula
placements.

The cannula tract and tip locations in these rats were

indistinguishable from those in the previous experiments, as they terminated within the B-8 5-HT cell group dorsal to the interpeduncular
nucleus.
Locomotor activity
A two-factor split-plot ANOVA with repeated measures on one factor
(Kirk, 1968; Bruning and Kintz, 1977, pp. 55-61) failed to reveal a significant effect of bicuculline methiodide on locomotor activity.

Only
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the

time

p<O.OOOl].

after

injection

effect

was

significant

[F(4,96)=22.24,

Seizures were not observed in any of the animals following

the administration of the bicuculline doses used.
Conclusion
If direct activation of GABA receptors (as produced by muscimol)
or facilitation of GABA-ergic transmission (such as produced benzodiazepines) in the

~IR

results in hyperactivity, then blockade of GABA recep-

tors should have the opposite effect.

The data obtained in the present

experiment, however, do not support this view.

Intra-MR muscimol may

inhibit the firing rates of local 5-HT neurons.

According to the pre-

sent hypothesis, the resultant decrease in neurotransmitter release from
MR 5-HT efferent nerve terminals would result in the observed hyperkinesis.
at

Blockade of the inhibitory effects of endogenously released GABA
the

same

receptor

sites

(that

is,

on

serotoninergic neurons),

nevertheless, may not result in the opposite condition:

although it is

possible that MR 5-HT perikarya may increase their rate of discharge
immediately following their release from a tonic GABA-ergic inhibition,
this enhancement most likely would be followed by an almost immediate
return (within a fraction of a second) to the baseline due to collateral
feedback inhibition (Aghajanian and Wang, 1978).

Any transient increase

in 5-HT release from MR efferent nerve terminals would, thus, not be of
long enough duration to bring about a hypokinetic response.
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IVc:
INTERACTIONS OF INTRA-RAPHE BENZODIAZEPINES WITH MUSCIMOL
Procedure
Cannulae were implanted in the MR nuclei of 14 rats as described
in the

Materials and Methods

section

(Chapter II)

Seven rats

were

assigned to the flurazepam - muscimol group and 7 to the midazolam muscimol grQup.

In this experiment, animals received either saline veh-

icle, or a sub-effective dose (0. 22 nmole) of flurazepam or midazolam
into the MR 5 minutes prior to the administration either of saline (0. 5
~1)

or of a sub-effective dose of muscimol (0.22 nmole).

Otherwise, the

procedure was the same as that in Experiment II.
A repeated measures - two factors ANOVA design was used for the
statistical analysis of the behavioral data (Bruning and Kintz,

1977,

pp. 48-54).
Results

Histological analysis
The behavioral data from 3 rats were eliminated prior to statistical analysis, since the cannula placements in these animals were localized 1.5 - 2.5 mm lateral to the MR.

The cannula tips terminated in the

B-8 5-HT cell group dorsal to the interpeduncular nucleus in the 5 rats
comprising the flurazepam - muscimol group, and in the 6 rats forming
the midazolam - muscimol group.
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Locomotor activity
Flurazepam-muscimol interaction.

An ANOVA of the total 2 hour

post-injection activity scores demonstrated significant effects both of
muscimol [F(1,26)=187.73, p<0.0001] and of flurazepam [F(1,26)= 173.38,
p<0.0001].

The effects of flurazepam and muscimol, moreover, interacted

[F(1,26)=161.00,

p<0.0001].

Individual

comparisons,

however,

showed

that only the combined injection of flurazepam and muscimol produced
significant

elevations

over

the

vehicle-injected

control

condition

(Table 1).

This observation accounts for the significant effects of

muscimol and flurazepam mentioned above.
Midazolam-muscimol interaction.

An ANOVA of

the total 2 hour

post-injection activity scores demonstrated significant effects both of
muscimol [F(1,27)= 168.06, p<0.0001] and of midazolam [F(1,27)=137.64,
p<O. 0001].

Similar to the results above, the effects of midazolam and

muscimol interacted [F(1,27)=165.76, p<0.0001].

Individual comparisons

showed that only the sequential injections of midazolam and muscimol
together produced activity scores significantly higher than those after
vehicle injections (Table 1).

This observation accounts for the signi-

ficant effects of muscimol and midazolam reported above.
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TABLE 1
Interaction of intra-raphe benzodiazepines with muscimol.
Total activity scores (Mean+/- S.E.M.)

following injection

of muscimol (0.22 nmole) or saline (0.5 Jll) through cannulae
chronically indwelling in the median raphe nucleus.

Five

minutes

were

prior

to

receiving

injected with flurazepam
(0.22 nmole; n

= 6)

muscimol,

(0.22 nmole;

or saline (0.5 pl).

the

animals

n = 5),

midazolam
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TOTAL 2-HOUR POST-INJECTION ACTIVITY SCORES

DOSE MUSCIMOL

DOSE
BENZODIAZEPINE

VEHICLE

0.22 NMOLE

FLURAZEPAM
VEHICLE

1848 ± 175

2251 ± 366

FLURAZEPAM
0.22 NMOLE

2078 ± 174

5769 ± 392*

MIDAZOLAM
VEHICLE

1200 ± 182

1201 ± 165

MIDAZOLAM
0.22 NMOLE

1006 ± 95

5530 ± 126t

*

Significantly different from muscimol vehicle plus
flurazepam vehicle condition (p<0.001);

t

Significantly different from muscimol vehicle plus
midazolam vehicle condition (p<0.001, Student's ttest, 2-tailed).
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Conclusion
Our previous dose-response analysis

(Experiment II) had demons-

trated that muscimol in a dose of 0. 22 nmole (25 ng) did not produce
significant elevations in activity level.

The 0.22 nmole dose of either

flurazepam and midazolam also was below that required to induce hyperactivity

(Experiment

IVa).

However,

when

the

subeffective dose

(0. 22

nmole) of muscimol was injected immediately following the intra-raphe
administration of either benzodiazepine, a hyperkinetic effect was produced which was of the same magnitude as that of a four-fold higher dose
(0. 88 nmole)
observations

of muscimol
support

the

alone,

as

illustrated

conclusion that

in Figure

12.

the benzodiazepines

These
act by

facilitating the post-synpatic effects of endogenously released GABA and
of GABA agonists.
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Figure 12:

Interaction of intra-raphe benzodiazepines with
muscimol

Cumulative activity scores (Hean +/- S.E.M.) 15, 30, 60, 90
and 120 minutes following injection of muscimol (0.22 nmole)
or saline (0. 5 J.ll) through cannulae chronically indwelling
in

the

median

receiving

raphe

muscimol,

nucleus.
the

flurazepam (0.22 nmole; n
6) or saline (0.5 pl).

Five

animals

= 5),

minutes

were

prior

injected

to
with

midazolam (0.22 nmole; n

=

The vehicle-muscimol 0.88 nmole data

were obtained in Experiment IVd, which was conducted at the
same time as the present experiment.
S. E. M.)

The control means (+/-

were obtained in the same manner as

reported

in

Figure 11.

'b<:

significantly

elevated

over

the

corresponding

saline-

injected control condition (p<O.Ol, Newman-Keuls' test for
related measures).
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IVd:
INTERACTIONS OF INTRA-RAPHE BICUCULLINE METHIODIDE
AND MUSCIMOL
Procedure
Cannulae were implanted in the MR nuclei of 7 rats as described in
the Materials and Methods section (Chapter II).

In this experiment,

animals received either saline vehicle or bicuculline methiodide (0.88
nmole; 323 ng) into the MR 5 minutes prior to either muscimol (0. 88
nmole; 100 ng) or saline injection.

The procedure otherwise was identi-

cal to that employed Experiment II.
Results

Histological analysis
Of the 7 rats studied, 6 were found to have acceptable cannula
placements in the rostral MR.
Locomotor activity
An ANOVA
demonstrated

of

the

that

total

the

2 hour

effect

of

post-injection
muscimol

activity

scores

significant

was

[F(1,27)=814.13, p<O.OOOl], whereas that of bicuculline methiodide alone
was not.
mol

Furthermore, the effects of bicuculline methiodide and musci-

interacted

[F(1,27)=238.87,

intra-MR bicuculline

p<O.OOOl].

As

shown

methiodide completely blocked

in

Table

2,

the hyperactivity

produced by a subsequent injection into the MR of an equimolar dose of
muscimol.

102
Conclusion
The results from Experiments IV a - d suggest that the effects of
peripheral administration of benzodiazepines and bicuculline on intraraphe muscimol-induced hyperactivity probably are due to their interactions at the same GABA receptors within the midbrain.
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TABLE 2
Intra-raphe bicuculline interactions with muscimol.
Total activity scores (Mean +/- S.E.M.) for the 2 hour period

following

saline

the

(0. 5 }11)

injection of

through

the median raphe nucleus

muscimol

(0. 88

nmole)

or

cannulae chronically implanted in
(n

=

6).

Five minutes prior to

receiving muscimol or saline, the animals received bicuculline methiodide (0.88 nmole) or saline.
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TOTAL 2-HOUR POST-INJECTION ACTIVITY SCORES

DOSE
BICUCULLINE
METHIODIDE

*

DOSE MUSCIMOL
VEHICLE
0.88 NMOLE

VEHICLE

1638 ± 224

5210 ± 246*

0.88 NMOLE

1715 ± 235

1827

±

103

Significantly different from muscimol vehicle
plus bicuculline vehicle condition (p<0.001,
Student's ~-test, 2-tailed).
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Experiment Y..
MUSCIMOL DOSE-RESPONSE CURVE IN ANIMALS WITH LESIONS
OF THE VENTRAL TEGMENTAL NUCLEI OF GUDDEN
In vitro autoradiographic studies have demonstrated that whereas
the DR and MR are sites of only moderate benzodiazepine binding, the
ventral tegmental nuclei of Gudden (VTG) show extremely dense benzodiazepine labelling.

(Young and Kuhar,

1980;

Young

~

al.,

1981).

Since the benzodiazepines are thought to bind allosterically to a membrane complex including the GABA receptor, there is a correlation between the loci of benzodiazepine and GABA binding sites.

The VTG,

in

contrast t9 the DR and MR, are devoid of 5-HT perikarya (Steinbusch,
1981; Kulmala and Lorens, 1982).

Bilateral electrolytic lesions of the

VTG result in increased open field locomotor activity (Lorens
1975).

In contrast,

et al.,

5, 7-dihydroxytryptamine lesions of the ascending

serotonin pathways do not affect activity level in the open field (Lorens

et al., 1976; Lorens, 1978). Since the VTG lie immediately dorsola-

teral to the MR, it is possible that the locomotor effects of muscimol
injections into the MR may be due to diffusion to the VTG.

Activation

of GABA receptors located on VTG neurons could result in hyperpolarization and suppressed rates of firing.

This transient inhibition,

"functional lesion," could lead to locomotor hyperactivity.

or

We, there-

fore, ablated the VTG electrolytically in order to determine whether or
not this manipulation would affect the dose-response relationship for
muscimol.
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Procedure
Three groups of animals were employed.

One sham-operated control

group of 8 animals was anesthetized, the scalps incised and retracted,
and craniotomies performed.

The lesion electrode was not lowered into

the brain, nor were intracranial cannulae implanted.
groups, electrolytic VTG lesions (n
tions (n

= 8)

=

In the other 2

15) were produced or sham-opera-

were performed first; immediately thereafter MR cannulae

were implanted as described in the Materials and Methods section (Chapter II).

Behavioral testing began 2 weeks later.

Since bilateral elec-

trolytic destruction of the VTG has been reported to produce hyperactiv·
ity

in the

open

field and

to facilitate

acquisition

(shuttlebox) conditioned avoidance task (Lorens

of a. two-way

et al., 1975; 1976),

these two tests were used to screen the animals behaviorally for effec·
tive VTG lesions prior to the initiation of the intra-raphe muscimol
study.

Thus, only lesion animals with both open field activity scores

and total avoidance responses above

control range subsequently were

tested for a muscimol dose-response relationship in the photocell activity cages.

In addition, the locus and effectiveness of the VTG lesions

were assessed histologically and biochemically as described previously
(Lorens

et al., 1975).

Open field activity
Open field activity was tested in a 100 x 100 em arena with 40 em
high walls.

Illumination was provided by a 15-watt bulb centered 120 em

above the arena.

The floor of the open field was painted white and
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divided by black lines into 25

equal squares.

Animals naive to the

apparatus were placed in the center square at the start of the test.
Crossings from square to square with all four limbs were recorded by the
experimenter at 3 minute intervals for 9 minutes.
Two-way conditioned avoidance
Rats were trained to avoid footshock in a 100 em long, 24 em wide
and 30 em high shuttlebox illuminated with a 40-watt fluorescent tube
mounted outside the rear wall.

The front wall was composed of clear

Plexiglas, while the remaining surfaces were of translucent white Flexiglas.

The test chamber was divided by a 7.5 em high metal hurdle into

two equal sized compartments.
floor

connected

by

a

Each side of the chamber contained a grid

selector

E-1064-GS shocker and scrambler.

switch

to

a

Grayson-Stadler

model

A 4 ohm speaker was mounted in each

wall for the delivery of a 75 decibel white noise conditioned stimulus
(CS).

The ambient noise level approximated 50 -55 decibels.
Acquisition of the two-way avoidance resP,onse was examined begin-

ning 7 days after completion of open field testing.

A single session of

50 massed trials was given to each VTG lesion animal which was hyperactive in the open field, and to each cannulated and non-cannulated control animal.

The first training trial started 3 minutes after the rat

was placed in one of the compartments.
45 seconds.

The intertrial interval was 30 -

The CS was terminated when the rat crossed into the oppo-

site compartment.

The unconditioned stimulus, a 0.8 milliampere conti-

nuous footshock, was administered if the animal failed to cross the bar-
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rier within 5 seconds after CS onset.
recorded, but not punished.

Intertrial barrier crossings were

Escape and avoidance latencies were mea-

sured with a stopwatch.
Muscimol dose-response
analysis
Beginning 1 week after completion of two-way avoidance testing,
the animals were tested for locomotor activity in the photocell chambers
using a procedure identical to that described in Experiment II, with the
exception that activity levels were recorded every 15 minutes for only
one hour post-injection.

The doses of muscimol employed were 0, 50, 100

and 200 ng.
Results

Histological analysis
Of the 15 animals on which both VTG lesions and MR cannulations
were performed, only 10 that met the behavioral criteria for effective
VTG lesions and included in the drug study.

Of these, only 6 had well

placed cannulae in the B-8 5-HT cell group dorsal to the interpeduncular
nucleus (Figure 13) and subsequently were analyzed behaviorally and biochemicaly.

Since the cannula placements in the 8 control animals were

similar to those in the accepted lesion subjects, none of these animals
was rejected from the study.

109

Figure 13:

VTG lesion and MR cannula placement sites.

Reconstruction of damage (blackened area) in the VTG lesion
rats.

Black circles with arrows

tips.

Numbers identify individual animals.

Abbreviations:
nucleus,

indicate

loci of cannula

cniV = trochlear nucleus, dr =dorsal raphe

dtg = dorsal tegmental nucleus of

interpeduncular nucleus,

Gudden,

ipn =

mr = median raphe nucleus,

vtg =

ventral tegmental nucleus of Gudden;

DBC = decussation of

brachium conjunctivum, ML = medial lemniscus, MLF = medial
longitudinal fasciculus.
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Biochemical analysis
The striatal and hippocampal concentrations of 5-HT and its metabolite, 5 -HIAA, were assayed by HPLC.
pared:

The following groups were com-

the animals with acceptable VTG lesions and MR cannulae (n = 6),

the sham-operated animals with MR cannulae (n = 8), and the sham-operated non-cannulated controls (n = 8).

As shown in Table 3, hippocampal

5-HT levels in the VTG lesion animals were significantly reduced in comparison with both the sham-operated controls (57%) and the MR cannulae
implanted controls

(52%).

The hippocampal 5-HIAA levels in the VTG

lesion rats showed similar reductions.

In contrast, the striatal 5-HT

concentrations of the 3 groups did not differ significantly.
tal 5 -HIAA level in the VTG lesion rats,
lower (18%) than the control level.

The stria-

however, was significantly

These observations are in agreement

with those reported by Lorens and coworkers (1975).

Importantly, the MR

cannula placements by themselves did not significantly affect the concentration of 5-HT in either the hippocampus or the striatum.

Although

the hippocampal 5-HIAA level of the sham-operated MR cannulated rats was
slightly but significantly lower than control (24%), these data suggest
that the MR cannulae did not significantly damage the 5-HT perikarya
comprising, or the 5-HT fibers emanating from, the B-8 5-HT cell group.
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TABLE 3
Effects of VTG lesions on regional 5-HT and 5-HIAA levels.
Hippocampal

and

striatal

5-hydroxytryptamine

(5-HT)

and

5-hydroxyindoleacetic acid (5-HIAA) concentrations (Mean+/S.E.M.
mals.

ng/g wet tissue mass) in VTG lesion and control aniData entries represent Mean+/- S.E.M.
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STRIATAL AND HIPPOCAMPAL 5-HT AND 5-HIAA LEVELS
IN VTG LESION AND NON-LESION ANIMALS

HIPPOCAMPUS
TREATMENT

n

SHAM-OPERATED
CONTROL

STRIATUM

5-HT
(ng/g)

5-HIAA
(ng/ g)

5-HT
(ng/g)

5-HIAA
(ng/g)

8

416 ± 27

743 ± 55

607 ± 22

937 ± 34

MR.-CANNULA
ALONE

8

370 ± 33

564 ± 30*

600 ± 22

898 ± 37

VTG LESION+
MR.-CANNULA

6

179 ± 31*t

343 ± 28*t

619 ± 26

767 ± 35*

*

Significantly different from sham-operated controls (p<0.01);

t

Significantly different from MR-cannula alone (p<0.01, NewmanKeuls' multiple range test).
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Behavioral analysis
Open Field Activity and Conditioned Avoidance Acguitision.

These

two behavioral tests were used to screen the effectiveness of the VTG
lesions.
the

Only the ranges of scores obtained from the rats accepted for

intra-raphe muscimol

dose-response analysis

are presented.

The

ranges of total 9-minute open field activity scores were as follows: MR
cannula implanted plus VTG lesion group (n = 6), 365 - 521; sham-operated MR cannula implanted group (n = 8), 128 - 298; sham-operated noncannulated group (n = 8), 52 - 235.
conditioned avoidance responses
were:

The ranges for the total number of

emitted during

the 50 massed trials

animals with VTG lesions and implanted MR cannulae, 28

- 43;

sham-operated rats with MR cannulae, 9 - 27; sham-operated controls, 1 26.

The group of rats with VTG lesions plus MR cannulae also tended to

show more inter-trial spontaneous barrier crossings (2 - 248) during the
entire test session (about 45 minutes in length) than either the non-lesion MR cannula implanted (0 - 22) or the sham-operated non-cannulated
control (O - 14) groups.
Muscimol Dose-Response Analysis.

An ANOVA

(three factor mixed

design- repeated measures on two factors; Bruning and Kintz, 1977, pp.
62 - 72) of the

30 minute pre-injection activity levels of the rats

with VTG lesions and MR cannulae, versus the non-lesion rats with implanted MR cannulae for the 4 drug days revealed both significant group
[F(1,10)=30.66, p<0.0005] and time [F(1,10)= 112.44, p<O.OOOl] effects.
This latter effect was due to the greater level of activity of the animals during the first 15 minutes in the apparatus.
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A subsequent ANOVA of the total 60 minute post-injection activity
scores for the 4 drug days showed neither significant group nor interaction

effects.

[F(3,30)=11.86,

As

expected,

p<O.OOOl].

the

dose

Muscimol

effects

produced

were

significant

similar dose-dependent

elevations in activity level in both groups (Figure 14).

Because the

animals with VTG lesions evidenced higher baseline levels of activity
than the non-lesion subjects, we reexamined the post-muscimol effects
after taking this difference into consideration.

For this purpose the

activity scores obtained by each rat during the last 15 minutes of the
pre-drug control period were subtracted from each of its four 15-minute
post-injection scores.

An ANOVA of these data also failed to demons-

trate any significant difference between the VTG lesion and control
groups.

As expected, the muscimol dose effect was significant [F(3,30)

=16.68, p<0.0001], but the group-dose interaction was not.
Conclusion
These data suggest that the

GABA and benzodiazepine receptors

located on neuronal cell bodies or fibers within the VTG do not mediate
the hyperkinetic effects of intra-raphe muscimol administration.
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Figure 14:

Effects of VTG lesions on muscimol-induced
hyperactivity.

Dose-response relationship for muscimol injections through
cannulae chronically implanted in the median raphe nucleus
of

rats

with bilateral

nuclei of Gudden (VTG, n
Total activity scores

lesions

= 6)

in

the

ventral

tegmental

or control operations (n

(Mean +j-

S.E.~1.)

period following muscimol injection.

for

= 8).

the one hour
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experiment VI
MUSCU10L DOSE-RESPONSE CURVE IN ANIMALS WITH LESIONS
OF THE ASCENDING 5-HT PROJECTIONS
We have found benzodiazepine binding sites in the MR, although not
~

as dense as in the VTG (Sainati

al., 1982). Since destruction of the

VTG had no effect on the locomotor response to intra-raphe muscimol, and
since the peripheral administration of benzodiazepines has been reported
to diminish 5-HT turnover in the CNS, we decided to determine the effect
of forebrain 5-HT depletion on the effects of intra-raphe muscimol.
Procedure
The

ascending

5-HT

5,7-dihydroxytryptamine

projections

(~,7-DHT)

were

destroyed

by

intracerebroventricularly (n

injecting

=

12) or

intramesencephalically (n = 12) as described in the Materials and Methods section (Chapter II).

These animals, as well as vehicle-injected,

controls, were implanted with MR cannulae during the same operative session.

Beginning 2 weeks post-operatively the animals were tested as in

Experiment II, again with activity counts recorded every 15 minutes for
one hour post-injection.

At the end of the experiment, the animals were

sacrificed by decapitation, their hippocampal and striatal 5-HT levels
assayed by HPLC, and their brainstems fixed in buffered formalin for
histological verification of cannula and mesencephalic 5,7-DHT injection
sites.
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Results

Histological analysis
Of the animals which survived the entire experiment, 7 rats which
had been injected intraventricularly with 5,7-DHT, 7 animals which had
received intraventricular injections of the vehicle,

7 which had been

injected intramesencephalically with 5,7-DHT, and 6 which had been given
vehicle injections into the mesencephalon had cannulae well localized
within the B-8 5-HT cell group, dorsal to the interpeduncular nucleus.
In addition, the sites of the intramesencephalic 5, 7-DHT and vehicle
injections were ex·amined and all found to be appropriately localized
within the course of the ascending 5-HT projections through the ventral
tegmental area of Tsai, or immediately dorsal to the rostral tip of the
interpeduncular nucleus (Figure 15).

The histological appearance of the

5,7-DHT and vehicle injection sites were virtually indistinguishable.
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Figure 15:
Site

of

Photomicrograph of a midbrain 5,7-DHT injection
site.
a

typical

intra-mesencephalic

5,7-dihydroxy-

tryptamine (5,7-DHT) injection (4.0 pg in 2.0 )11 vehicle,
bilaterally)
Cresylecht

is

demarcated

violet

stained

represents 1 mm.

by
50

Abbreviations:

a
~m

glial
coronal

scar

(arrows).

section.

Bar

Aq = cerebral aqueduct of

Sylvius, IPN = interpeduncular nucleus, R =red nucleus.
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Biochemical analysis
The 5-HT and 5-HIAA concentrations in the neostriata and hippocampi of the control animals which had received intracerebroventricular
vehicle injections (Table 4) were virtually the same as those for the
sham-operated control animals in Experiment V (Table 3).

Intraventricu-

lar 5, 7 -DHT reduced the 5 -HT concentrations in both the striatum (95%)
and hippocampus
tions.

The

(83%) as compared to intraventricular vehicle injec-

intramesencephalic 5, 7-DHT injections

reduced the 5-HT contents of the striatum (77%)

also significantly
and the hippocampus

(59%) as compared to the intra-midbrain vehicle injections.

Similar

reductions were seen in the regional concentrations of the 5-HT metabolite, 5-HIAA.

Intramesencephalic vehicle injections in comparison to the

intraventricular vehicle injections, produced a small (22%), insignificant reduction in the hippocampal 5-HT concentration, but a significant
(37%) fall in hippocampal 5-HIAA content (Table 2).

This observation,

supported by the histological data, suggests that the intra-midbrain
vehicle injections interrupted some of the 5-HT fibers which innervate
the hippocampus.
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TABLE 4
Effect of 5,7-DHT on regional 5-HT and 5-HIAA levels.
Hippocampal

and

striatal

5-hydroxytryptamine

(5-HT)

and

5-hydroxyindoleacetic acid (5-HIAA) concentrations (Mean+/S.E.M.
with

ng/g wet tissue mass) in control animals and animals
intra-midbrain

and

intraventricular

tryptamine (5,7-DHT) lesions.

5,7-dihydroxy-
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STRIATAL AND HIPPOCAMPAL 5-HT AND 5-HIAA LEVELS
IN ANIMALS WITH INTRAVENTRICULAR OR
INTRA-MIDBRAIN 5,7-DHT LESIONS

HIPPOCAMPUS
TREATMENT

n

INTRAVENTRICULAR
VEHICLE

7

INTRAVENTRICULAR
5,7-DHT

7

INTRA-MIDBRAIN
VEHICLE

6

INTRA-MIDBRAIN
5,7-DHT

I

7

STRIATUM

5-HT
(ng/g)

5-HIAA
(ng/g)

5-HT
(ng/g)

5-HIAA
(ng/g)

464 ± 49

741 ± 64

526 ± 61

824 ± 76

76 ± 13*t§
. 362 ± 34
148 ± 15*§

60 ± 18*i·§

28 ± 6*t§

102 ± 23*t§

470 ± 62*

542 ± 99

757 ± 69

168 ± 41*§

123 ± 35*§

327 ± 54*§

*

Significantly different from intraventricular vehicle (p<0.01);

t

Significantly different from intra-midbrain 5,7-DHT (p<O.Ol);

§

Significantly different from intra-midbrain vehicle (p<0.01,
Newman-Keuls' multiple range test).
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Behavioral analysis
An ANOVA (three factor mixed design - repeated measures on one
factor; Bruning and Kintz, 1977, pp. 62 - 72) of the pre-drug baseline
activity levels of the 4 groups of rats failed to reveal any significant
5,7-DHT lesion effect, regardless of the mode of its production (intraventricular versus intramesencephalic).

However, an ANOVA (three factor

mixed design - repeated measures on two factors;

Bruning and Kintz,

1977, pp. 73 - 84) of the effects of intra-raphe muscimol injections
showed the following.

The effects of the dose of muscimol were signifi-

cant [F(3,72)=6.28, p<0.002], as were the effects of time after injection {F(3,72)=14.59, p<0.0001].

In addition,

the effects of lesion

group and of muscimol dose interacted [F(9,72)=7.26, p<O.OOl].

Indivi-

dual comparisons of the total 60 minute post-injection activity level
for each group confirmed that both types of forebrain 5 -HT-reducing
lesion markedly attenuated the effects of intra-raphe muscimol (Figure
16).
Conclusion
The data obtained from the present experiment suggest that the
hyperkinetic

effect

of

intra-midbrain

raphe

depend on an intact ascending 5-HT fiber system.

injections

of

muscimol
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Figure 16:

Forebrain 5-HT depletion blocks the effect of
muscimol.

Dose response relationship for the injection of muscimol (0,
50, 100 or 200 ng) through cannulae chronically implanted in
the

median

raphe

nucleus

5,7-dihydroxytryptamine
cerebral

ventricles

of

rats

(5,7-DHT)

(75

)lg

which

had

injections

bilaterally),

received
into

or

into

the
the

ascending 5-HT fibers at the level of the red nucleus (4.0
J.lg bilaterally).

Group mean

(+/- S.E.M.) activity scores

for the 1 hour post-injection period are presented.

't:

significantly

elevated

over

saline-injected

condition (p<0.01, Newman-Keuls' test for related

control

measures)~

t

significantly elevated over intra-midbrain 5,7-DHT,

§

significantly elevated over intra-ventricular 5,7-DHT,

#

significantly elevated over intra-midbrain vehicle

(p<O.Ol, Newman-Keuls' multiple range test).
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CHAPTER IV

DISCUSSION
General Discussion
Overall,

the present series of

experiments

injection of the GABA agonist, muscimol,

indicates that the

into the mesencephalic raphe

results in a dose-dependent hyperkinetic response which is mediated by
an ascending serotonergic system.

The present observations also suggest

that GABA receptors within the midbrain raphe regulate the discharge
rate of 5-HT neurons whose forebrain efferents modulate motor systems,
and that the benzodiazepines can modify the activity of these systems
centrally.
The first experiment confirmed previous findings

(PrzewJocka

et

al. 1979) that acute microinjection of muscimol (100 ng) into the dorsal
raphe nucleus produces hyperactivity as measured in photocell chambers.
In addition, the median raphe nucleus was found to be even more sensitive to muscimol (100 ng) than the dorsal raphe nucleus, the magnitude
of the hyperkinetic effect being four times greater after injection into
the former site.

The acute injection paradigm employed by Przewtocka

and associates (1979), and in Experiment I, required that the subjects
be tested immediately upon awakening from the ether anesthetic.

Thus,

it was not possible to discern whether the hyperactivity produced was
due to muscimol alone, or to the interaction between muscimol, ether and
the trauma of surgery.
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In order to circumvent this problem, a muscimol dose response-analysis was conducted using animals with cannulae implanted chronically
into either the dorsal or the median raphe nucleus (Figure 5).

Since

each animal received each drug dose, this experiment used a Latin square
design in order to determine any order of treatment effects.

Accord-

ingly, injection of muscimol into the median raphe nucleus produced a
significant elevation in activity level at one-fourth the dose (50 ng)
required to produce a similar effect when injected into the dorsal raphe
nucleus.

The hyperkinetic response following the injection of an opti-

mal dose of muscimol (100 ng) into the median raphe nucleus, moreover,
was at least 1.5 times more marked than the response to an injection
(200 ng) of muscimol into the dorsal raphe nucleus (Figure 6).

As there

was no effect of order of treatment, subsequent experiments were performed using a randomized block design.
The observed four-fold greater sensitivity of • the median raphe
nucleus as compared to the dorsal raphe nucleus raises the possibility
that the hyperkinesis

following muscimol

injections into the dorsal

raphe nucleus may be due, at least in part, to a spread of the drug to
the more sensitive median raphe site.
vivo autoradiographic

We have begun a series of

studies to determine

the time course

in

and the

extent of the spread of radiolabel following injections of various doses
of

3

H-muscimol through cannulae chronically implanted in the dorsal and

median raphe nuclei of rats.

Our preliminary results suggest that fol-
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lowing injections of

3

H-muscimol (50 ng) into the median raphe nucleus,

the greatest density of the label remains concentrated around the guide
cannula tip, even 60 minutes post-injection.

A light, but significant

density of label, however, has spread by this time nearly 1. 0 mm ventrally, caudally and rostrally.

Such a spread of muscimol from the tip

of a cannula in the dorsal raphe nucleus
nucleus.
al.

includes the median raphe

It is of interest to note in this regard that PrzewJocka

(1979)

et

fou.nd decreases in 5-HT and 5-HIAA concentrations in the

hypothalamus, but not in the neostriatum, following the injection of
muscimol (25 - 100 ng) into the dorsal raphe nucleus.
Chapter I,

As reviewed in

substantial evidence has been advanced demonstrating that

5-HT fibers afferent to the neostriatum arise predominantly in the dorsal raphe nucleus (B-7 5-HT cell group), whereas the 5-HT projection to
the hippocampus originates principally in the B-8 5-HT cell group, which
overlaps the caudal linear and median raphe nuclei.

In addition, For-

chetti and Meek (1981) have reported that muscimol injections into the
median raphe nucleus reduce 5-HT turnover in the hippocampus.

Thus, the

hyperkinetic response to intra-dorsal raphe muscimol injections observed
by Przewlocka and collaborators might have been due to a spread of the
muscimol to

the median

raphe nucleus

(B-8 5-HT cell group).

This

hypothesis currently is under investigation in our laboratory.
As stated earlier, several reports implicate GABA as a neurotransmitter in both the dorsal (Belin

~

al., 1979; Forchetti and Meek,

1981; Gallager, 1978; Gallager and Aghajanian, 1976; Massari

et al.,
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1976; Paul -et ---..,
al.,
Meek, 1981).

1981) and the median raphe nucleus

(Forchetti and

Many of the behavioral and physiological effects of the

benzodiazepines are believed to be due to their facilitation of GABA-ergic transmission (Cook and Sepinwall, 1975; Costa and Guidotti, 1979;
Costa

et al., 1981; Gallager, 1978; Paul et al., 1981).

If the effects

of intra-mesencephalic administration of muscimol were due to activation
of GABA receptors in the raphe nuclei, they should be potentiated by
benzodiazepines

(for

example,

chlordiazepoxide)

and blocked

by

the

GABA-receptor antagonist, bicuculline.
In a preliminary study (Sainati and Lorens, 1981) we found that
intraperitoneal administration of chlordiazepoxide in doses greater than
3.8 mg/kg produced decreases in locomotor activity as measured in dark
photocell chambers to which the animals had been habituated previously.
Lower doses produced no effect on activity level.

These findings are

consistent with other reports demonstrating that although the benzodiazepines enhance exploratory behavior in novel environments, they have
little effect on activity level when the animals are tested in settings
to which they have been habituated (Marriott and Spencer, 1965; Christmas and Maxwell, 1970; Krsiak

et al., 1970; Pieri et al., 1981).

It was found (Experiment III) that peripheral administration of
chlordiazepoxide, in the sub-ataxic dose of 3. 8 mg/kg, did not itself
affect activity level, but enhanced the locomotor activity response to
low doses
nucleus.

(25 and 50 ng) of muscimol injected into the median raphe
Conversely, a subconvulsant dose of bicuculline ( 1. 1 mg/kg)

completely blocked the response to 50 and 100 ng of muscimol.
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If benzodiazepine compounds do act to facilitate GABA-ergic transmission, it seemes plausible to hypothesize that intra-raphe administration of representative benzodiazepines might produce increases

in

locomotor

by

activity.

We

tested

(Experiment

IVa)

this

hypothesis

injecting three different water-soluble benzodiazepines (chlordiazepoxide,

flurazepam and midazolam) directly into the median raphe nucleus

through chronically indwelling cannulae.

Water soluble compounds were

chosen in order to avoid any potential behavioral effects that might
ensue from the use of a non-aqueous vehicle.

The ethanol-propylene gly-

col vehicle commonly used to dissolve non-water soluble benzodiazepines
most likely would have deleterious
brain.

~ffects

if injected directly into the

We found that injections of flurazepam and midazolam directly

into the median raphe nucleus both produced dose-dependent increases in
locomotor activity (Figure 10).

Flurazepam, moreover, produced a maxi-

mal hyperkinetic effect at a dose one-half as great as that required for
midazolam.

This observation is

consistent

with the hypothesis

that

these compounds act on two different allosteric sites on a benzodiazepine-GABA-receptor complex (Costa and Guidotti, 1979; Olsen, 1982).

The

greater potency of flurazepam over midazolam in inducing hyperactivity
also is in keeping with the relative order of potencies of these drugs
in displacing radiolabeled benzodiazepines from binding sites
(Nohler and Okada, 1977;
Nielsen, 1980) .

Braestrup and Squires, 1978;

in vitro

Brasetrup and
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The failure of chlordiazepoxide both to induce hyperactivity when
injected
3

into

the

median

H-flunitrazepam binding

raphe

nucleus

in

vivo,

and

to

displace

in vitro (Sainati et al., 1982), is further

evidence that chlordiazepoxide is a pro-drug which must be converted to
active metabolites in order to have an effect in the central nervous
system (Greenblatt and Shader, 1974; Johnson and Rising, 1979; Breimer
et al., 1980; Harvey, 1980).
The benzodiazepines are thought to act post-synaptically by binding at a site on a large receptor-ionophore complex allosteric to the
GABA binding site, and thereby increase the affinity of the latter for
its ligand.

If so, then the GABA agonist, muscimol, and the centrally

active benzodiazepines should have additive hyperkinetic effects when
injected one after the other directly into the median raphe nucleus.
Indeed combining a sub-effective dose of muscimol with a sub-effective
dose of either flurazepam or midazolam produced hyperkinetic effects as
robust as a four-fold higher dose of muscimol alone (Figure 12).
If

facilitation of GABA-ergic neurotransmission

in the median

raphe nucleus produced hyperactivity, then blockade of GABA receptors
might be expected to have the opposite effect.

However,

bicuculline injections did not affect activity level.

intra-raphe

This observation

is not surprising, since release from tonic GABA-ergic inhibition (Forchetti and Meek, 1981) would result in an initial brief increase in the
firing rates of 5-HT neurons, followed by an almost immediate return to
baseline due to collateral

feedback inhibition

(Aghajanian and Wang,
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1978).

On the other hand, the intra-raphe injection of bicuculline did

block the hyperkinetic effect of muscimol, providing additional evidence
that the muscimo1 effect is due to a direct activation of GABA receptors
within the raphe.
The ventral tegmental nuclei of Gudden (VTG) lie just dorsolateral
to the median raphe nucleus.

Bilateral electrolytic lesions in the VTG

produce hyperactivity similar to that seen after electrolytic lesions in
the median raphe nucleus.

The VTG are sites of dense benzodiazepine

receptor localization (Young and Kuhar,

1980).

In vitro autoradio-

graphic studies currently in progress in our laboratory confirm this
finding (Sainati

!! al., 1982).

Furthermore, benzodiazepine receptors

usually are associated with GABA receptors (Costa and Guidotti, 1979;
Paul

et al., 1981).

GAD (Nassari

Although not a particularly rich source of GABA or

et al., 1976), the VTG receive a significant afferent pro-

jection from the ipsi- and contra-lateral dorsal tegmental nuclei of
Gudden (Briggs and Kaelber, 1971; Petrovicky, 1973), which contain high
levels of GAD.

It seemed entirely possible, therefore, that the hyper-

activity induced by intra-raphe muscimol injections could be due to diffusion of the drug to GABA-ceptive sites located in the VTG.

We, there-

fore, destroyed the VTG in order to determine whether this manipulation
would attenuate the hyperkinetic effect of intra-raphe muscimol injections.

We found, in agreement with earlier findings

(Lorens

et al.,

1975), that the VTG lesions increased open field activity and facilitated the acquisition of a two-way conditioned avoidance response.

In
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the darkened activity chambers, the VTG lesion animals also manifested
higher baseline levels of activity than controls, but the lesions failed
to attenuate the facilitatory effects of muscimol.

Thus , it appears

that the effects of intra-raphe muscimol on locomotor activity and of
VTG lesions on this behavior, are independent phenomena.
Subsequently, forebrain 5 -HT was depleted by injecting the specific serotonin neurotoxin,

5, 7-dihydroxytryptamine,

lateral

or

cerebral ventricles

into

the midbrain

into

either the

tegmentum.

These

lesions markedly attenuated the locomotor response produced by muscimol
injections into the median raphe nucleus.

These data suggest that mid-

brain GABA neurons modulate activity level in the rat through a direct
action on mesencephalic serotonergic neurons.
As

a

result,

we

hypothesize

that

when

muscimol

is

injected

directly into the midbrain raphe nuclei, it suppresses the firing rate
of serotonergic neurons by activating local GABA receptors.

This, in

turn, elicits locomotor hyperactivity by releasing hippocampal (Williams
and Azmitia, 1981) or substantia nigra (see below) neurons from a tonic
serotonergic inhibitory influence.

Intraventricular and intramesence-

phalic 5,7-dihydroxytryptamine lesions, however, did not alter baseline
activity level in our photocell chambers.

Biochemical analysis showed

that these lesions resulted in a degeneration of forebrain 5-HT efferents, but histological analysis indicated that their perikarya of origin were spared, possibly because of sustaining collaterals.

It may be

that in order to induce hyperactivity the 5-HT cell bodies associated

136
with the midbrain raphe nuclei themselves must be destroyed.

Also, dur-

ing the 2 week post-lesion recovery period, the motor systems of the
animals

may

adapt

to

the

loss

of

the

ascending

5-HT projections.

Nonetheless, the link between the midbrain GABA-ceptive site normally
responsible for

inducing hyperactivity,

motor behavior still are lost.

and

the areas which control

Thus, the acute inhibition of 5-HT neu-

rons following intra-raphe muscimol produces hyperactivity, whereas a
lesion which chronically destroys ascending 5-HT projections allows a
new, compensated "steady state" to develop.
The neuronal mechanisms by which a GABA-ergic inhibition of raphe
5-HT cells might produce elevations in locomotor activity is largely a
matter of speculation.

There is a substantial amount of evidence to

support the existence of inhibitory 5-HT projections from the dorsal and
median raphe nuclei to the substantia nigra in the rat (Dray
1976; 1978; Nicolaou et al.,
Giambalvo

and

Snodgrass

et al.,

1979; van der Kooy and Hattori, 1980a).

(1978)

report

that

5,7-dihydroxytryptamine

injections into the median raphe nucleus, i f placed 0. 3 mm lateral to
the midline, produce a "unilateral" lesion.

Such lesions cause rats to

rotate in a direction contralateral to the site of injection, the rotation being blocked by haloperidol.

They found a significant correlation

between the rate of rotation, the decrease in cortical 5 -HT turnover,
and the increase in striatal dopamine turnover.
that

Moreover, they found

injections of 5, 7-aihydroxytryptamine into the substantia nigra

itself produced biochemical and behavioral changes similar to those following 5,7-dihydroxytryptamine injections into the median raphe nucleus.
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The nigrostriatal dopamine pathway is an important component of
the extrapyramidal motor system. The indirect dopamine agonist, amphetamine, and the dopamine-receptor agonist, apomorphine, both can induce
turning in rats with unilateral lesions in the nigrostriatal dopamine
system

(Ungerstedt

and Arbuthnott,

1970;

Ungerstedt,

1971).

These

drugs, however, induce turning in opposite directions.

Amphetamine is

thought

dopamine

intact

to produce

ipsilateral

contralateral striatal

thought to induce

turning by releasing

nerve terminals,

from

while apomorphine

is

contralateral turning by stimulation of supersensi-

tive dopamine receptors in the denervated ipsilateral striatum.
If unilateral stimulation of striatal dopamine receptors produces
rotation in a direction contralateral to the site of stimulation, then
bilateral stimulation of striatal dopamine receptors might produce a
non -rotational hyperactivity.
injections

of muscimol

In our experiments, midline intra-raphe

hypothetically would

suppress the

inhibitory

raphe-substantia nigra 5-HT pathway, producing a bilateral increase in
the firing rates of nigral dopamine neurons.

This, in turn, would lead

to a non-rotational, stereotypic hyperkinesis.
In summary, the present results suggest that midbrain raphe 5-HT
neurons exert a tonic inhibitory effect on CNS systems which influence
locomotor behavior.

Temporary removal of this inhibition by administer-

ing the GABA agonist, muscimol, or the benzodiazepines, flurazepam and
midazolam, into the mesencephalic raphe results in hyperactivity.

Thus,

this forebrain 5-HT system appears to be regulated by raphe GABA inter-
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neurons, whose post-synaptic effects can be facilitated following the
administration of benzodiazepine drugs.
Proposals for Future Research
If, as stated above, intra-raphe injections of muscimol produce

hyperactivity by suppressing an inhibitory raphe-substantia nigra 5-HT
pathway, then the effect of muscimol should be prevented by the administration of a dopamine antagonist,

such as haloperidol.

Haloperidol

would be expected to block the hyperkinetic effects of the hypothesized
increased dopamine release from the nigra-striatal pathway.

Further-

more, nigral lesions using 5,7-dihydroxytryptamine might produce elevations in activity level, and should prevent the hyperkinetic effect of
intra-raphe muscimol injections.
Although the dorsal and median raphe nuclei (Taber, 1960) contain
serotoninergic neurons,

such cells

these two nuclear groups (Aghajanian
1979; Steinbusch
inbusch,

1981;

are not the sole constituents of
~

al., 1978; Descarries

~

al.,

et al., 1980; van der Kooy and Steinbusch, 1980; SteKulmala and Lorens,

1982).

The following

series of

experiments is proposed, therefore, to determine the relative importance
of the 5-HT efferents from the dorsal and median raphe nuclei in the
mediation of intra-raphe muscimol induced hyperkinesis.
Huscimol dose response analysis will be performed in animals with
selective 5,7-dihydroxytryptamine lesions of the dorsal or median raphe
nucleus, as well as in subjects with combined lesions of both nuclei.
These results will be compared to those obtained from appropriate con-
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trol animals, and to data from rats with ibotenic acid lesions of the
dorsal and/or median raphe nucleus.

Ibotenic acid is an excitotoxic

isoxazole compound which selectively destroys neuronal cell bodies at
the site of application while sparing axons of passage and nerve terminals of extrinsic origin (Schwarcz,

~

al., 1979a; 1979b).

It appears,

moreover, that the somata of neurons which use a biogenic amine (such as
5-HT)

as

a neurotransmitter

are relatively

resistant

to

the

toxic

effects of ibotenic acid (R. Schwarcz, personal communication; S.A. Lorens,

unpublished

observations).

Thus,

5, 7 -dihydroxytryptamine and ibotenic acid,

these

two

neurotoxins,

could be used to produce

relatively specific lesions of midbrain 5-HT· and non-5-HT·containing
neuronal perikarya, respectively.
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